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ABSTRACT 
 
Eisenmenger syndrome is characterised by severe, lifelong hypoxaemia and pulmonary 
hypertension. Despite this, patients do surprisingly well and report a reasonable quality of life. 
This thesis describes a series of experiments investigating the adaptations that occur in these 
patients in response to the chronic hypoxaemia. 
 
Patients with Eisenmenger syndrome have severely limited exercise tolerance when assessed 
using cardiopulmonary exercise testing. However, they appear to maintain aerobic 
metabolism until late on in exercise. Studies using skeletal muscle 31P MRS during and 
throughout recovery from exercise showed that these patients have similar mitochondrial 
oxidative capacity compared to healthy controls. 
 
Echocardiography showed that patients with Eisenmenger syndrome have preserved right and 
left ventricular systolic function. However they have evidence of right ventricular diastolic 
dysfunction as evidenced by impaired early diastolic relaxation.  The cardiac 31P MRS study 
demonstrated that despite the normal systolic function shown on echocardiography, there is 
impairment of septal energetics as revealed by a reduction in PCr/ATP ratio.  
 
The results presented in this thesis indicate that adult patients with Eisenmenger syndrome 
have undergone beneficial adaptations to the severe hypoxaemia that they are exposed to from 
infancy. 
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1. INTRODUCTION 
 
1.1  Eisenmenger Syndrome 
1.1.1 Background  
In 1897 Victor Eisenmenger described the post mortem findings of a large ventricular septal 
defect (VSD) and pulmonary hypertension in a patient with a history of cyanosis from infancy 
who died of haemoptysis aged 32 years[1].  However, Eisenmenger attributed the cyanosis to 
poor systemic circulation and inadequate ventilation rather than shunt reversal. It was not 
until 1924, that Abbot and Dawson attributed the cyanosis to shunt reversal[2] and 1947, 
before pulmonary hypertension was suggested as the cause for the shunt reversal by Bing et 
al[3].  Subsequently the term Eisenmenger complex was used to describe “pulmonary 
hypertension at the systemic level of arterial pressure, due to a high pulmonary vascular 
resistance, with a reversed or bidirectional shunt through a large ventricular septal defect”[4].  
 
Paul Wood subsequently noted that the site of the shunt matters little and, in his Croonian 
lectures in 1958, coined the term Eisenmenger syndrome to describe the pathophysiology of 
cyanotic patients with pulmonary hypertension at systemic levels with high pulmonary 
vascular resistance due to a shunt at atrial, ventricular or arterial level, associated with 
reversed or bidirectional shunting and cyanosis[4]. He described 12 different anatomical 
abnormalities that may all develop an Eisenmenger physiology (table 1.1). 
 
1.1.2 Pulmonary Hypertension in Congenital Heart Disease 
Some degree of pulmonary arterial hypertension (PAH) is found in 5-10% of adults with 
congenital heart disease[5] with Eisenmenger syndrome being at the severe end of the 
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spectrum of pulmonary hypertension.  There is a considerable degree of heterogeneity within 
pulmonary hypertension associated with congenital heart disease, both in the level of 
pulmonary vascular resistance and in the outcome. Thus patients with similar underlying 
conditions may develop PAH of variable severity; this stresses the need for accurate 
classification of ACHD patients with PAH. One method of classification is summarised in 
table 1.2.  
 
1.1.3 Aetiology of Eisenmenger Syndrome  
Progressive histological changes are seen in the pulmonary vasculature in patients with 
pulmonary hypertension secondary to congenital heart disease; Heath and Edwards described 
6 different grades in 1958[6]. Since then it has become clear that increased pulmonary blood 
flow due to a significant left to right shunt causes endothelial damage by shear stress and 
circumferential stretch[5] with subsequent release of growth factors. Various growth factors 
have been linked with the pathophysiological changes seen in PAH including transforming 
growth factor β. This induces vascular smooth muscle cell (SMC) proliferation and 
hypertrophy and SMCs are seen extending into the vascular bed and also neointima 
formation[5;7]. The endothelial damage also causes activation of platelets and leukocytes, 
increased levels of endogenous vasoconstrictors including endothelin I and thromboxane and 
decreased levels of vasodilators  such as prostacyclin, nitric oxide and vasoactive intestinal 
peptide[7-9]. These changes eventually lead to vasoconstriction and pulmonary vascular 
remodelling with occlusion of medium and small pulmonary arteries by excessive cellular 
proliferation and in-situ thrombi[5;8].  These histological findings are present in all forms of 
pulmonary hypertension. 
 
 3
With progressive remodelling of the pulmonary vasculature, the pulmonary vascular 
resistance (PVR) increases and thus the pulmonary artery pressure also rises. Eventually, the 
pulmonary artery pressure reaches suprasystemic levels and the shunt is reversed (right to left) 
leading to cyanosis and Eisenmenger syndrome[4;10].  
 
Currently, the abnormalities resulting from endothelial damage that have been translated into 
clinical practice as targets for intervention are down-regulation of the prostacyclin axis, down-
regulation of the NO/cGMP axis and up-regulation of the endothelin axis[11;12]. Future 
therapies are likely to focus on reversal of the pulmonary vascular remodelling and may 
involve the final common pathways e.g. tyrosine kinase. 
 
1.1.4 Epidemiology of Eisenmenger Syndrome 
 In the 1950s Eisenmenger syndrome accounted for approximately 8% of all congenital heart 
disease[4].  Due to the advent of cardiopulmonary bypass, advances in paediatric cardiology 
and improved diagnosis, Eisenmenger syndrome is now largely preventable in most children 
with congenital defects; as a result the incidence has fallen to <4% in modern cohorts in 
developed countries[13;14]. However, Eisenmenger syndrome is likely to continue to occur at 
high rates in developing countries where there may be restricted access to paediatric surgery 
or limited health care sources. 
 
1.1.5 Natural History of Eisenmenger Syndrome 
Patients with Eisenmenger syndrome are chronically hypoxaemic with resting oxygen 
saturations of <90% in room air and with further desaturation on exercise[5]. They are prone 
to the multi-organ complications of chronic hypoxaemia.  These effects are cardiac 
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(progressive heart failure, endocarditis, paradoxical emboli), haematopoietic (erythrocytosis, 
hyperviscosity syndrome, neutropenia, thrombocytopenia and bleeding disorder), pulmonary 
(haemoptysis, pulmonary artery thrombosis), neurological (strokes, cerebral abscesses), renal 
(proteinuria, progressive renal failure) and metabolic (hyperuricaemia, pigment gallstones and 
renal calculi)[15].  
 
These complications might be expected to adversely affect the quality of life of patients with 
Eisenmenger syndrome. However, Daliento et al suggested otherwise when they assessed the 
natural history of 188 patients with Eisenmenger syndrome [16]. A standardised Ability Index 
questionnaire was used for functional assessment (appendix 1) which assesses the patient’s 
ability to lead a normal life[17].  In this study, the majority of patients reported a satisfactory 
Ability Index (1 and 2) suggesting a good quality of life at initial presentation, with one third 
being in full-time employment. Increasing age is associated with clinical deterioration with 
84% of patients reporting a significant reduction of effort tolerance at a mean age of 28± 13.5 
(SD) years.   
 
Despite the many effects that chronic hypoxaemia and pulmonary hypertension has on 
patients with Eisenmenger syndrome, it is also notable that these patients actually do 
surprisingly well with a reasonable long term prognosis. From the same study by Daliento et 
al, a survival of up to 55% at 55 years was seen[16]. Further, Diller et al noted that these 
patients have a good short term prognosis, but overall a reduced life expectancy with a 
survival at 40, 50 and 60 years of age of 94, 74 and 52% respectively[18]. This is in contrast 
to patients with idiopathic pulmonary arterial hypertension (IPAH) who have comparable 
levels of pulmonary hypertension to that seen in Eisenmenger syndrome, but who have an 
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estimated median life expectancy of three years following diagnosis[19]. Similarly patients 
with chronic lung disease and persistent hypoxaemia have a 50% three year mortality[20]. 
Factors associated with a worse prognosis in Eisenmenger syndrome included poor right 
ventricular function, complex underlying cardiac anomaly, elevated creatinine level and non-
cardiac surgery. 
 
1.1.6 Purpose of Work 
The purpose of the studies described in this thesis was to investigate the physiological 
adaptations that have occurred in response to chronic hypoxaemia and pulmonary 
hypertension in adult patients with Eisenmenger syndrome. Specifically we have looked at the 
exercise performance, skeletal muscle adaptations and cardiac function in these patients.  
Whilst these areas have previously been investigated extensively in both patients with 
different forms of congenital heart disease and other groups with profound hypoxaemia, little 
is known as to how these patients adapt so well to survive often into their fifth or sixth 
decade, with a reported good quality of life.   
 
1.2 Exercise Intolerance in Eisenmenger Syndrome  
Despite the generally reasonable Ability index score described by patients with Eisenmenger 
syndrome[16], this group do have severely impaired exercise tolerance when measured 
objectively with cardiopulmonary exercise testing (CPEX) with peak VO2 being markedly 
lower than healthy controls[21-23]. Diller et al compared the exercise capacity of patients 
with different forms of congenital heart disease[24]. Overall cyanotic patients performed 
worse than non-cyanotic and those with Eisenmenger syndrome performed the worse of all 
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with peak VO2 11.5±3.6ml/kg/min. They found that low peak VO2 was associated with a poor 
outcome including increased hospitalisation and death. 
 
Patients with Eisenmenger syndrome are also noted to have an impaired ventilatory efficiency 
during exercise, as shown by a high VE/VCO2 slope, with an inverse correlation between 
resting O2 saturations and the VE/VCO2 slope[25;26]. Thus, cyanosis is thought to be a 
powerful stimulus for the abnormal ventilatory pattern observed during exercise. Whilst a 
high VE/VCO2 slope is again known to be associated with a poor outcome and predicts 
increased hospitalisation rates and mortality in patients with chronic heart failure and non-
cyanotic congenital heart disease, Dimopoulos et al did not find this in cyanotic patients[26]. 
This may be due to different causes of the ventilatory inefficiency in this group of patients 
such as a significant hypoxic contribution to the ventilatory control. 
 
1.3 The Right Ventricle  
1.3.1 Right Ventricular Structure 
The right ventricle (RV) is triangular in shape and is formed of three anatomical and 
functional subunits; the inlet portion, the body and the infundibulum.  In normal 
circumstances it is thin walled with the free wall 3-5mm in thickness[17;27].  
 
The myocardium is composed of a mesh of myocytes within fibrous tissue.  The myocytes 
have a predominantly longitudinal orientation and join with other myocytes to form 
myofibres[28].  It is these bundles of myofibres that generate the contractile force of the 
ventricles. The RV differs from the LV in the orientation of the layers of the myofibres.  It has 
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a superficial layer of circumferential or transverse fibres that are arranged parallel to the 
atrioventricular groove and a deep layer that lie longitudinally from apex to base[28].  
 
The interventricular septum is now known to be the central component of the relationship 
between the RV and LV[29] and also has an important role in determining  RV function, with 
Saleh et al describing the septum as “the lion of RV function”[30]. The septum is made up of 
oblique / helical fibres compared to the predominantly transverse orientation of the RV free 
wall[31]. The septum’s resultant twisting action was described by Borelli in 1681 as “like 
wringing a cloth”[32]. It is the orientation of these myofibres that dictates the contractile force 
produced by the ventricle[29]. Rushmer et al demonstrated that contraction of only 
circumferential fibres results in an ejection fraction of 30%[33]. Contraction of oblique fibres, 
however, results in an ejection fraction of 60%[34].   
 
In normal conditions of low pulmonary vascular resistance (PVR), the inward bellows-like 
activity of the circumferential fibres, with some contribution from the septum, is able to 
generate sufficient force to maintain cardiac output[35]. However, as PVR increases, helical 
fibres assume an increased importance to contract effectively against the increased 
afterload[30]. 
 
1.3.2 Right Ventricular Function in Eisenmenger Syndrome 
Patients with severe pulmonary hypertension (PHT) due to Eisenmenger syndrome have a 
better survival when compared to patients with idiopathic or acquired forms of PHT, despite 
an associated cardiac anomaly and chronic hypoxaemia[36;37]. Hopkins hypothesised that the 
key to their relative longevity lies in the adaptations undergone by the RV[37]. In 
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Eisenmenger syndrome, RV function is typically preserved and clinical heart failure 
uncommon[38-40]. The majority of deaths are secondary to intrapulmonary haemorrhage or 
rupture of a major vessel[41]. 
 
Throughout gestation the fetal heart has equal systolic pressures in the aorta, pulmonary 
artery, left ventricle (LV) and RV due to a non-restrictive ductus arteriosus. Thus, there is 
equal RV and LV wall thickness in utero[42]. In normal hearts, changes begin shortly after 
birth with regression of the RV wall due to the closure of the ductus arteriosus and reduction 
in right sided pressures[37]. However, in the presence of a persistent and large left to right 
shunt, the RV appears to be “primed” in a pre-Eisenmenger phase and adapts for a lifetime of 
functioning at systemic pulmonary pressures[43]. The hearts of adults with Eisenmenger 
syndrome resemble fetal hearts rather than normal adult hearts with equal RV and LV wall 
thickness. This is in comparison to IPAH, for example, in which normal regression of RV 
wall thickness occurs in infancy.   
 
1.3.3 Right Ventricular Function in Other Conditions with High RV Afterload 
The RV structure and function in other conditions associated with elevated RV pressures have 
been previously studied. Sanchez-Quintana et al compared the ventricular myoarchitecture of 
hearts from patients with unrepaired tetralogy of Fallot (ToF) and normal hearts. They found 
that the RVs of the patients with ToF have a more oblique arrangement of their superficial 
fibres and also an extra middle layer of circumferential fibres[44]. They hypothesise that these 
adaptations reduce radial wall stress and may preserve short axis function. Pettersen et al 
demonstrated that the systemic RV in patients with a previous atrial switch for transposition 
of the great arteries (TGA) have a predominant circumferential over longitudinal systolic 
 9
function[45].  This is in contrast to normal circumstances when the majority of the force 
generated from the RV is through longitudinal deformation. This again may be due to 
increased circumferential fibres in the RV myocardium. Tan et al studied RV function in 
patients with TGA who have undergone an atrial switch, congenitally corrected TGA 
(ccTGA) and IPAH[46].  They show that patients with ccTGA had overall better RV function 
due to the RV adapting to the increased afterload from birth and having faced no surgical 
insults. 
 
In Eisenmenger syndrome, RV failure has been shown to be associated with a poor 
outcome[16;16] and is the main cause of death in PAH from all causes[47]. 
 
1.4 Skeletal Muscle 
1.4.1 Skeletal Muscle Structure and Function 
The principal roles of skeletal muscle are to allow skeletal movement and give support to the 
skeleton to maintain posture.  Skeletal muscle is made up of multiple cylindrical muscle 
fibres, each containing multiple nuclei and mitochondria, arranged close to the sarcolemma in 
the longitudinal axis of the muscle[48]. Within skeletal muscle there are both thick filaments, 
containing predominantly myosin, and thin filaments, containing mainly actin[48]. These 
filaments are arranged into bundles, known as myofibrils, and it is these myofibrils that give 
the characteristic striated appearance of skeletal muscle. 
 
Myosin has projections, known as cross bridges, which bridge the space between adjacent 
thick and thin filaments[48;49].  These cross bridges generate force during contraction of the 
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muscle by making contact with the actin of the thin filaments. The resulting movement of the 
thick and thin filaments over one another is termed the sliding filament mechanism[48].   
 
Blood vessels run between the fibres with arterioles supplying blood to a capillary network 
with the capillaries running alongside and occasionally over the muscle fibres[48;49]. The 
vascular bed functions to oxygenate muscle fibres and the muscle fibre’s oxidative capacity 
correlates strongly with the capillary density[50]. 
 
Different fibre types exist within skeletal muscle and can be distinguished by their ATP 
forming pathways and maximum velocity of shortening[51]. Type I fibres are “slow” fibres 
and have numerous mitochondria with a high capacity of oxidative phosphorylation (thus 
termed slow-oxidative). The fibres are surrounded by numerous capillaries supplied by a 
dense network of arterioles that deliver O2 and fuel at high blood flow. Type I fibres contain 
high levels of myoglobin, an O2-binding protein that binds O2 very effectively at low PO2 
values.  Type I fibres resist fatigue and are thus useful in endurance exercise. Type II fibres 
are “fast” and larger in diameter. They have fewer mitochondria, increased concentrations  of 
glycolytic enzymes as well as significant glycogen stores.  They have the capacity to use both 
oxidative and anaerobic metabolism depending on the subtype.  They have a less dense 
arteriolar and capillary supply and the fibres have little myoglobin, which reflects their 
limited use of O2.  In humans the main subtypes are type IIa (fast-oxidative) which have an 
intermediate resistance to fatigue and type IIb fibres (fast-glycolytic) which fatigue rapidly. 
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1.4.2 Energy Metabolism in Striated Muscle 
Muscle contraction is an active process requiring energy and this energy is generated 
predominantly by adenosine triphosphate (ATP) hydrolysis which breaks the high energy 
bond to release energy as shown in the following equation: 
ATP + H2O → ADP + Pi + H+ + energy 
Each contracting muscle fibre requires vast amounts of ATP (approximately 2500 ATP 
molecules per second per thick filament)[49]. However, resting fibres have only small 
reserves of ATP and therefore, further mechanisms are required to generate the required ATP 
during contraction. The generation of ATP within the mitochondria and muscle fibre is shown 
in figures 1.1 and 1.2. 
 
1.4.2.1 Phosphorylation of Adenosine Diphosphate (ADP) by PCr Hydrolysis 
At the onset of muscle contraction PCr is rapidly hydrolysed and as a result ADP is 
phosphorylated to form ATP, a reversible reaction catalysed by creatine kinase (CK). 
PCr + ADP      ATP + Creatine 
This transfer of energy is very rapid as it is a single enzyme reaction. Levels of ATP in the 
muscle fibre therefore change little whereas PCr concentrations drop quickly. This process is 
limited by cellular PCr concentrations. 
    
1.4.2.2 Oxidative Phosphorylation of ADP in Mitochondria 
This is the final stage in the aerobic metabolism of glucose, fatty acids and amino acids and 
occurs at the inner mitochondrial membrane, only in aerobic conditions. It provides up to 95% 
of the ATP demands of the resting cell[52].  Hydrogen atoms are transferred through a series 
CK 
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of oxidation and reduction reactions known as the electron transport chain.  The net result is 
the combining of protons and electrons with O2 to form water and the release of ATP.  
 
1.4.2.3 Substrate Level Phosphorylation of ADP by Glycolysis in the Cytosol  
Glycolysis is the pathway that generates pyruvate from glucose. It is an anaerobic process and 
generates just 2 molecules of ATP.  In aerobic conditions the pyruvate enters the TCA cycle 
and subsequently undergoes oxidative phosphorylation. In conditions when the availability of 
O2 is exceeded by the rate of glycolysis however, the conversion of pyruvate to acetyl CoA is 
inhibited, through the inhibition of the pyruvate dehydrogenase enzyme complex, and the 
pyruvate is converted to lactic acid. Glycolysis is important when the mitochondrial 
production of ATP is limited by the availability of O2. The production of lactate has a low 
yield of ATP per molecule of glucose, with just 2 ATP molecules being produced compared 
to 34 when oxidative phosphorylation can proceed. 
 
1.4.2.4 Fuel for ATP Production 
From the above it can be seen that the dominant fuels used in human skeletal muscle are 
glucose (both blood borne and from the breakdown of glycogen stores) and fatty acids (from 
muscle triglyceride stores and from plasma) through β-oxidation. Although fatty acids have a 
higher ATP yield per molecule compared to glucose (129 moles ATP per mole of palmitate 
versus 38 moles per mole of glucose), they do so at a higher O2 cost. The ATP synthesised/ 
O2 consumed ratio for glucose is 3.19 whereas for palmitate, it is 2.80[53]. 
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1.4.3 Skeletal Muscle Metabolism and Exercise  
1.4.3.1 Skeletal Muscle ATP Generation During Exercise  
At the start of exercise the rapid hydrolysis of PCr provides the required ATP, allowing time 
for the slower pathways of glycolysis that utilise multiple enzymes and also for oxidative 
phosphorylation to increase ATP production, and because this hydrolysis does not require O2 
there is an initial lag of around 45 seconds before O2 consumption reaches steady state during 
fixed rate exercise [54]. The PCr stores become depleted rapidly with sustained contraction 
with levels depleted by >60% after 9 seconds of intense exercise[55]. Thus with longer 
duration exercise, there is an increased demand for ATP from other sources along with an 
increase in O2 consumption.  In health, O2 availability is not a limiting factor and in steady-
state exercise, ATP production relies primarily on aerobic metabolism through oxidative 
phosphorylation[56-58].  However, at peak exercise, the maximal mitochondrial ATP 
production is limited by O2 availability and increasing levels of ATP are produced by 
anaerobic glycolysis, with recruitment of fast-glycolytic fibres[59].   
 
Immediately following exercise the O2 demand is still elevated. This is termed the O2 debt and 
refers to the amount of O2 needed to restore pre-exertion conditions including PCr, ATP and 
glycogen concentrations[49]. In healthy subjects, O2 is now readily available and PCr 
recovery is primarily aerobic[60;61]. Thus, PCr resynthesis reflects mitochondrial oxidative 
capacity with PCr resynthesis being faster in slow fibres with high oxidative capacity, than in 
fast glycolytic fibres[62]. It is also faster, following submaximal exercise, in exercise-trained 
subjects than in sedentary subjects, due to their increased muscle oxidative capacity[63-65].  
Haseler et al also showed that in trained athletes, the PCr recovery rate was limited by O2 
delivery and can be increased by giving supplementary O2. This contrasted with the situation 
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in sedentary subjects in whom supplementary O2 did not change PCr recovery indicating that 
in them the rate of recovery is limited by the mitochondrial oxidative capacity[63;66].  
 
1.4.3.2 Fuel Utilisation during Exercise  
At rest and during moderate exercise (up to 60% of mVO2), fats are the primary source of fuel 
for skeletal muscle[59;67;68]. With increasing exercise intensity and duration, glycogenolysis 
and glycolysis increase and there is increased recruitment of fast-glycolytic fibres.  Thus, 
there is an increased reliance on the more oxygen-efficient use of carbohydrates[59]. 
 
The rate of skeletal muscle oxidation is related to the mVO2, oxidative power, fibre type 
composition, insulin sensitivity, size of fuel stores, exercise intensity and duration, 
sympathetic nervous system activity and substrate availability[69]. 
 
It is well known that phenotypical adaptations of skeletal muscle occur in endurance athletes. 
These include an increase in fatty acid oxidation with less lactate production and less 
utilisation of glycogen and blood glucose with matching of glycolysis to TCA cycle-turnover, 
during exercise of a given intensity[59;70].  Muscle biopsies from endurance trained athletes 
show a higher mitochondrial content, increased capillary density and increased oxidative 
enzymes[69;71]. 
 
1.4.4 Control of Mitochondrial Respiration  
Under conditions of aerobic work, oxygen consumption and major ATP production occur in 
the mitochondria. The main parameters that control oxidative metabolism are oxygen and 
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substrate supply and the intracellular transfer of energy, most importantly the creatine / 
phosphate (Pi) system[72-74].   
 
Working muscle needs to regulate the steps of ATP production so that production is equal to 
utilisation and homeostasis is obtained when this occurs[75;76]. The sum of the 
concentrations of PCr and Pi is constant during exercise and, providing pH is constant, 
[Pi]/[PCr] is proportional to [ADP][60].  Chance et al showed that the principle role in the 
control of oxidative metabolism is by ADP rather than ATP or phosphate. ADP exhibits a 
negative feedback on ATP synthesis[74;75] with ATP synthesis having a hyperbolic 
dependence on [ADP][60]. PCr recovery following exercise, which reflects the mitochondrial 
oxidative capacity, is also limited by oxygen availability and intracellular acidosis with pH 
being responsible for altered states of the CK reactions[77].     
 
1.4.5 Skeletal Muscle Fatigue 
Fatigue is defined as “any decline in muscle performance associated with muscle activity and 
may manifest as a decreased peak force or a decreased ability to maintain a force”[78].  There 
is both central and peripheral fatigue arising proximal and distal to the neuromuscular 
junction respectively[79].  For the purpose of this discussion only peripheral fatigue is 
considered below as our study has looked at skeletal muscle adaptations.  
 
The development of peripheral fatigue is considered to be mediated by metabolic by-products 
that accumulate during muscle contraction, the rate of their accumulation being O2-
dependent[79]. That at least part of the mechanism was O2-dependent is also shown by Fordy 
and Marshall who demonstrated that breathing 40% O2 rather than air during the recovery 
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from a period of maximum voluntary forearm contraction to exhaustion greatly improved the 
time to exhaustion during a second period of forearm contraction[80]. The substances 
currently implicated in the development of fatigue are potassium ions (K+), inorganic 
phosphate (Pi) and hydrogen ions (H+). Lactate, produced as a result of anaerobic metabolism, 
was also traditionally implicated in the development of fatigue. However, muscle lactate 
levels have been shown to poorly correlate with fatigue and so is an unlikely 
contributor[81;82]. Reactive oxygen species (ROS) have also been linked to fatigue and their 
role is also briefly discussed below in 1.4.5.4.  
 
1.4.5.1  K+ and Fatigue 
Increasing concentrations of K+ ions are seen both within muscle interstitium[83] and arterial 
and venous blood[84] during exercise.  K+ is released from muscle fibres during exercise as a 
result of the KIR channels remaining open in response to decreasing ATP levels. K+ is then 
taken back up by the cell via Na+/K+-ATPase[85;86]. A number of human studies have linked 
a rise in extracellular K+, as evidenced by increased interstitial K+ or plasma concentrations, 
with a decreased time to fatigue[83;87;88]. Further, Clausen and Nielsen demonstrated that 
pre-incubation of rat skeletal muscle with 10mM K+ caused a decrease in initial force and an 
increased rate of force decline in muscle relative to that seen when incubation in 4mM K+ 
solution was performed[89].  
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1.4.5.2 Inorganic Pi and Fatigue 
Pi is produced during muscle contraction due to the breakdown of PCr, via ATP hydrolysis. 
Pi accumulation occurs when the supply of ATP from the breakdown of PCr exceeds the 
consumption of ATP[78;90]. 
 
Pi is implicated in both phase I and III of fatigue (see Allen DG 2009 for full review of the 
phases of fatigue)[91].  In phase I there is an initial reduction in force to 80-90% of control 
due to the inhibitory effect of the increasing Pi concentrations on the myofibril cross bridges. 
In phase III, a further reduction in force is caused by  the attenuation of the contractile 
proteins’ sensitivity to calcium (Ca2+) as well as a  decrease in the release of Ca2+ from the 
sarcoplasmic reticulum, both due to the elevated Pi concentration[78].   
 
The association between Pi and fatigue is well documented. Cooke et al demonstrated that 
injecting increasing concentrations of Pi to rabbit psoas muscle fibres resulted in a decreased 
isometric force.  Further to this, studies on CK knockout (CK -/-) mice by Dahlstedt et al 
showed that, although the CK-/- mice had higher resting Pi levels, Pi did not increase with 
exercise and these mice, on exercise, showed reduced fatigability.  
 
1.4.5.3 H+ and Fatigue 
H+ accumulates in muscle when ATP hydrolysis exceeds the rate of mitochondrial respiration 
due to the following reaction [90]: 
ATP + H2O      ADP + Pi + H+ 
Traditionally, accumulation of H+ during muscle contraction was implicated in the 
development of fatigue with single fibre studies showing a decreased shortening velocity and 
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isometric tension with decreasing pH[92;93].  However, more recent studies have shown poor 
temporal correlation between H+ concentration and fatigue and, as a result, H+ are considered 
unlikely to be directly responsible for peripheral fatigue at physiological temperatures[94;95]. 
H+ may play an indirect role by stimulating group III and IV nerve afferents to cause 
discomfort during exercise[96].    
 
1.4.5.4 ROS and Fatigue 
ROS are produced in active muscle and there is increasing support that they contribute to  
fatigue[78]. ROS produced in the muscle include superoxide, hydrogen peroxide, hydroxyl 
radicals and peroxynitrate, formed by the interaction between nitric oxide and superoxide.  
Their production is increased with increasing exercise intensity[97] and also temperature[98-
100]. 
 
The infusion of ROS scavengers, including N-acetyl cysteine (NAC) and superoxide 
dismutase (SOD), into isolated muscle preparations have demonstrated a smaller reduction in 
force and slower fatigue with intermittent contractions[101;102]. Moopanar et al 
demonstrated that the sensitivity of the muscle to fatigue increased with temperature, in a way 
that is consistent with increased ROS production[103].  These findings have been confirmed 
in human studies with Medved et al showing an increased time to volitional fatigue in 
subjects infused with NAC during submaximal cycling[104]. 
 
Despite the growing evidence for ROS and fatigue Allen et al note that uncertainties remain 
including the source of the ROS, which particular ROS is responsible and the mechanism by 
which they cause fatigue[78]. 
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To date, the substances implicated in peripheral fatigue have not been investigated in 
Eisenmenger syndrome.  
 
1.4.6 Skeletal Muscle Changes in Disease 
As indicated above, production of cellular energy by oxidative tissues occurs primarily by 
oxidative phosphorylation. Therefore, it follows that there must be a constant supply of both 
fuels and O2 for normal cellular function to occur. O2 supply may be impaired in different 
disease states and this may be due to hypoxaemia and / or a decreased delivery of O2 to the 
tissue. Hypoxaemia occurs in pulmonary diseases, for example chronic obstructive pulmonary 
disease, due to ventilation – perfusion (V/Q) mismatching and hypoventilation, or in the 
presence of a right to left shunt such as that seen in Eisenmenger syndrome. Reduced O2 
delivery may be caused by decreased O2 carrying capacity in anaemia or impaired perfusion 
of the tissue in heart failure or shock. It may also occur in the healthy individual at high 
altitudes due to the reduced barometric pressure of the atmosphere.  Skeletal muscle changes 
have been well documented in chronic heart failure (CHF) and chronic obstructive pulmonary 
disease. 
 
1.4.6.1 Chronic Heart Failure 
Exercise intolerance in patients with CHF is common, however it does not correlate well with 
central haemodynamics or left ventricular ejection fraction[105-107] suggesting peripheral 
abnormalities. Both reduced skeletal muscle blood flow and skeletal muscle mass have been 
demonstrated in patients with CHF[108], while biopsies show reduced mitochondrial density, 
fewer capillaries per fibre and an increase in type-IIb glycolytic fibres with a corresponding 
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decrease in type I oxidative fibres[109-111];. 31P-MRS studies have shown a greater 
magnitude of PCr depletion, a decreased pH and a slower PCr recovery time following 
regional exercise in these patients[112-114]. These changes correspond with the systemic 
exercise intolerance shown by Okita et al[112].  Further, Hanada et al  showed that PCr 
resynthesis was not significantly limited by haemoglobin re-saturation following exercise, 
which suggests that O2 utilisation has a bigger role in recovery than O2 delivery[113]. It has 
also been demonstrated that in skeletal muscle of CHF patients there are decreased levels of 
aerobic mitochondrial enzymes involved in terminal oxidation eg citrate synthetase but 
normal levels of glycolytic enzymes[110;115;116]. These results suggest a myopathy of 
metabolic origin in CHF with the decreased aerobic activity playing an important role in 
mediating the premature anaerobic metabolism and lactate accumulation seen during 
exercise[115]. 
 
1.4.6.2 Chronic Obstructive Pulmonary Disease 
COPD is a chronic debilitating condition that is also characterised by exercise intolerance. 
Traditionally the cause of the exercise limitation was considered to be primarily ventilatory, 
but more recently skeletal muscle dysfunction has been reported[117] with the true cause 
likely to be more complex with both ventilatory limitation and a peripheral component 
contributing[118].  Similar changes have been described as seen in CHF with muscle atrophy 
and decreased muscle strength[119], increased fatigability[117], a change in fibre type 
composition favouring glycolytic type-IIb fibres[120], reduced capillaries per fibre[121], a 
greater lactate accumulation on exercise[122] and a decrease in oxidative enzyme 
capacity[123].  31P-MRS studies have also shown a similar increased magnitude of PCr 
depletion with an increased PCr recovery time and reduced pH[124]. 
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1.4.6.3 Eisenmenger Syndrome 
Skeletal muscle of patients with Eisenmenger syndrome has not previously been studied.  It is 
known that these patients have similar degrees of exercise intolerance to patients with end 
stage heart failure[24] but whether they have the same metabolic myopathy is unknown.  
Also, as well as having abnormal central haemodynamics like in CHF, they also have 
profound hypoxaemia. The potential effects of this are discussed below. 
 
1.5 Hypoxia 
1.5.1 Background  
Hypoxia is defined as “a decrease in tissue O2 supply below normal levels”[71].  Hypoxaemia 
denotes a decreased oxygen tension in the blood, that is  a PaO2 less than normal[71;125]. The 
term dysoxia is used to define a deficiency at a cellular level and the PO2 at which this occurs 
must be defined[71]. Below this is a region of PO2 in which VO2 is limited by the availability 
of O2 and metabolic adaptations must occur to support mitochondrial ATP production.  PCrit0 is 
the lowest PO2 that can be considered normal and is tissue specific.  Below this ATP can only 
be produced by glycolysis with a resultant increase in lactate production. Mitochondria 
require PO2 of 0.13-0.4kPa to generate ATP to maintain aerobic cellular function[20].   
 
Hypoxia is an adverse environmental condition that organisms need to adapt to [126]. Chronic 
and systemic hypoxia can be considered physiological, that is not as a result of disease, in 
both the fetus and at high altitude[127].  
  
Grocott et al hypothesise that “hypoxic adaptive processes are likely to be common to tissue 
hypoxia whatever the cause”, such as that occurring in critical illness[128].  Much of the work 
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into how the body adapts to hypoxia has been performed using healthy individuals who are 
exposed to hypoxia through altitude. With increasing altitude the barometric pressure falls and 
the partial pressure of O2 (PO2) decreases linearly with the PO2. At the summit of Everest this 
is just 30% of that at sea level[129].  With falling inspired FiO2 resting arterial O2 saturations 
also decrease, down to 92% at 3000m and to 80% or lower at 5000m with an ambient PaO2 
85mmHg[130]. However, other stressors such as low ambient temperature and exercise, must 
be taken into account when looking at the effects of altitude[127]. 
 
Groups studied include those living at altitude and low land dwellers visiting altitude. The 
World Health Organisiation, in 1996, estimated that there were approximately 140 million 
people living at altitudes over 2500m including several areas at over 4000m[131]. Hoppeler et 
al used the following nomenclature to describe the hypoxic exposure of different groups[132]. 
Native to hypoxia implies that the resident population has been exposed to hypoxia for many 
generations and may have genetic modifications to improve performance at altitude. This 
includes the Tibetan Sherpas and the Quechas from the Andes, Peru. Permanent hypoxia is 
used for subjects who live under hypoxic conditions from birth until death, for example 
residents of La Paz, Bolivia, parts of which are 4000m above sea level.  Long term hypoxia is 
used for individuals who are brought into hypoxic environments for several weeks or months 
and thus may acclimatise, such as on mountaineering expeditions.  Short term hypoxia 
describes short bouts of exposure to hypoxia, lasting minutes to hours, with normoxic 
conditions between. 
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1.5.2 Hypoxaemia in Eisenmenger Syndrome 
Patients with Eisenmenger syndrome are permanently cyanotic from infancy until death. They 
are characterised by persistence of a relatively intact overall physiological performance 
despite the presence of PO2 and SaO2 values that must be close to the limits of survival.  In 
addition they have apparently normal brain function, moderate exercise capacity and good 
long-term survival suggesting that this group of patients must have adapted to the marked 
hypoxaemia[16]. The sections below outline some of the physiological adaptations to hypoxia 
in humans. 
 
1.5.3  Physiological Adaptations to Chronic Hypoxia 
Adolph defined adaptations as “modifications of organisms that occur in the presence of 
particular environments and circumstances” and were not necessarily limited to those that 
seem favourable to the individual[133].  In this thesis I have used the term “adaptation” to 
mean physiological changes that result from chronic exposure to hypoxia and have not 
covered responses resulting from acute hypoxia. 
 
1.5.4 Oxygen Kinetics 
O2 must be extracted from the air at the alveoli and delivered to the cells for metabolism. O2 
delivery is the product of cardiac output and the O2 content (CaO2)[134].  CaO2 can be altered 
by changes in the ventilation, pulmonary blood flow and Hb concentration. Cardiac output is 
discussed further below and is not covered here. 
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1.5.4.1 Oxygen Content 
Ventilation Ventilation increases progressively with altitude and there is a concomitant 
decrease in arterial PCO2 and alveolar CO2 i.e. increased alveolar ventilation [135;136]. 
Sutton et al demonstrated a fourfold increase in ventilation during a simulated climb of Mount 
Everest and this was predominantly due to an increased frequency (2.4 fold increase) rather 
than tidal volume which only increased by 1.3 fold[135]. Increased ventilation is a response to 
decreased PaO2 not O2 saturations or content and is mediated by peripheral arterial 
chemoreceptors in the carotid bodies[125].  This hypoxic ventilatory drive declines with 
acclimatisation to altitude, ageing and is also blunted in cyanotic congenital heart 
disease[125]. Chua et al have also demonstrated a blunted hypoxic chemosensitivity in 
chronic hypoxaemia secondary to cyanotic congenital heart disease[137].  
 
Haemoglobin Concentration  Hypoxia activates sensors within the kidneys which 
increases the expression of erythropoietin, augmenting the red blood cell mass and Hb 
through an increase in erythropoiesis[138;139]. The majority of O2 in the blood is carried 
bound to Hb and there is only a small amount dissolved in plasma, each gram of Hb carrying 
1.31ml O2 of when fully saturated[134]. The increase in Hb therefore helps to normalise the 
O2 content (O2 carriage), augmenting peripheral O2 delivery. 
 
Cerretelli et al demonstrated a 40% increase in Hb and RBC count with a concomitant 
increase in haematocrit after an expedition to Everest base camp (altitude 5350m)[140]. This 
increase in Hb was also shown by Radgran et al who showed that Danish lowland dwellers at 
altitude increased their Hb to similar level as Aymara natives who live in the Andes at altitude 
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of 5260m and he concluded that O2 delivery to periphery is secured primarily by increase in 
Hb[141].  
 
Pulmonary circulation  In response to alveolar hypoxia, small “resistance” 
pulmonary arteries actively vasoconstrict [142;143]. This results in blood being diverted away 
from poorly ventilated regions of the lung. This results in improved ventilation – perfusion 
matching, decreased shunt fraction and an improved systemic PO2.  This process is modulated 
upstream by the endothelium and downstream by Ca sensitisation of the contractile apparatus, 
in turn controlled by rho kinase[143]. The mitochondria likely act as sensors in this 
process[142]. The vasoconstriction is rapid, occurring within seconds of moderate hypoxia 
and results in an elevated pulmonary vascular resistance.  In the acute setting it is immediately 
reversed by breathing O2. However, Groves et al, in their simulated Everest expedition 
“Everest II”, showed that lowlanders at altitude for 2-3 weeks developed a degree of 
pulmonary hypertension, not fully reversed by breathing O2, suggesting that vascular 
remodelling has occurred[144].  The physiological effects of this pulmonary vascular 
remodelling was shown by Penaloza et al who demonstrated increased smooth muscle cells in 
the distal pulmonary artery branches and associated right ventricular hypertrophy in healthy 
high altitude dwellers [145].  
 
1.5.4.2 Oxygen Delivery  
On initial exposure to altitude a decrease in arterial O2 delivery to muscle during submaximal 
exercise is observed but, whilst SaO2 and erythropoiesis increase with acclimatisation, the 
overall delivery of O2 to tissues does not increase accordingly[130]. After acclimatisation at 
5260m, Calbet et al demonstrated that the haemoglobin concentration had increased by 36% 
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with a 21% increase in resting CaO2 thus resting O2 delivery to muscle can reach similar levels 
as seen prior to exposure[146]. However, during maximal exercise the systemic O2 delivery 
was 10% lower than at sea level and this was thought to be due, at least in part, to a reduction 
in cardiac output (CO)[147]. 
 
Increased arterial O2 content and SaO2 are offset by a decrease in the CO during exercise and 
decreased muscle blood flow[148;149]. Calbet et al demonstrated that blood flow to 
exercising muscles reduced from 6.61l/min to 4.81l/min after 8 weeks of exposure to 
5250m[150]. A higher vasoconstriction may contribute to the observed decrease in muscle 
blood flow; mean arterial pressures, systemic vascular resistance and leg vascular resistance 
are all elevated and there is a parallel increase in plasma noradrenaline levels[148;149].  Other 
reasons for the reduction in blood flow to muscles include a reduction in CO, a lower 
proportion of the CO supplying the exercising muscles, an increased haematocrit and 
decreased vascular reactivity to endogenous vasodilator substances[150].  
 
1.5.4.3 Oxygen Extraction 
The reduction in O2 delivery and cardiac output is compensated for by an increase in tissue O2 
extraction as shown by an increase in the arteriovenous O2 differential[130;135;151]. O2 
extraction is not impaired with altitude exposure with the offloading and diffusion of O2 from 
the Hb to the mitochondria being helped by a shift to the right of the O2 dissociation curve and 
an increase in the capillary density[150;152]. This allows cellular O2 delivery to match 
demand despite the reduction in systemic O2 delivery. Thus, the exercising muscles are 
capable of extracting the required O2 during submaximal exercise[130].  However, as exercise 
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intensity increases and maximum extraction levels have been reached, a reduction in VO2 will 
be seen. 
 
1.5.5 Oxygen Consumption and Exercise 
In the presence of hypoxia, adaptations of both physiological and metabolic processes must 
occur to allow adequate oxygenation of tissues in the event of further stresses, such as that 
imposed by exercise, occur. Hypoxia and exercise will have an accumulative effect that will 
influence the maximal exercise capacity and performance.  
 
Exercising at altitude, compared to sea level, results in an increase in the relative exercise 
intensity, as well as a more pronounced disturbance of homeostasis[153]. The primary reason 
is that although a given submaximal exercise task results in a similar VO2 at both sea level 
and altitude, the decline in VO2 at increasing altitudes means that it represents a higher 
proportion of the maximal VO2[130]. Thus, exercise performed at sea level will represent a 
higher proportion of the maximal exercise intensity when performed at altitude. 
 
At sea level there is a tight relationship between CaO2 and mVO2 and, in normoxia, mVO2 is 
set by O2 transport predominantly (75%) and peripheral factors in the remaining 25%[154].  
This relationship is diminished at altitude with the capacity for exercise decreasing 
progressively with increasing altitude[155] and the mVO2 changes little after 
acclimatisation[140]. This is despite a marked increase in O2 carrying capacity.  
 
Cerretelli et al demonstrated a decreased mVO2 in acclimated low land dwellers and high 
altitude natives[140]. They then showed that the mVO2 improved slightly by giving FiO2 1.0 
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but not to sea level values. They concluded that it is not due to cardiovascular O2 transport but 
changes in peripheral factor including the attenuation of effective blood flow to working 
muscles.  
  
It is now generally accepted that mVO2 is not limited by a single factor, as previously 
believed, but by multiple factors[156] including  cardiovascular O2 transport, lungs (such as 
ventilation and / or diffusion) and peripheral factors including reduced muscle blood flow, O2 
conductance[152] and reduced oxidative capacity of the skeletal mass[157;158].  
 
1.6 Skeletal Muscle and Hypoxia 
1.6.1 Skeletal Muscle Adaptations  
Alterations in the delivery of O2 to skeletal muscle can result in tissue hypoxia, leading to a 
wide range of metabolic abnormalities and ultimately culminating in contractile failure[159].  
Skeletal muscle is able to show marked phenotypic plasticity in response to hypoxia; its key 
problem being able to sustain sufficient levels of aerobic metabolism despite reduced O2 
availability[160]. 
 
One of the first papers looking at skeletal muscle changes in hypoxia was by Reynafarjee in 
1962. This reported an increase in oxidative enzyme activity and myoglobin concentration in 
Andean altitude natives (Peruvian miners) compared to low-land dwellers[161].  This led to 
the assumption that muscle oxidative capacity is increased in the presence of altitude hypoxia 
thus compensates for the environmental hypoxia[161]. These finding of high oxidative 
enzymes and myoglobin are now known to be likely due to the training status of the subjects 
as exercise is also known to be a stimulator of mitochondrial enzyme activity[132].  
 29
 
Subsequent studies have shown a decrease in the oxidative capacity with decreased 
concentrations of oxidative enzymes in skeletal muscle of low land dwellers exposed to 
hypoxia for prolonged periods[159;162;163]. In 1990 Hoppeler et al also demonstrated a 20% 
reduction of mitochondrial volume density in acclimatised lowlanders[164].  However, as the 
same capillary bed length remained, the O2 supply for the remaining mitochondria is likely to 
be improved.  A similar decrease in oxidative capacity, along with a corresponding fall in 
capillarity, is seen in permanent high altitude residents[165;166].  Compared to lowland 
dwellers, however, they have low intracellular lipid deposits that did not increase with 
training[166;167].  The authors suggest that this may represent a shift towards favouring 
carbohydrates for metabolism over lipids with permanent exposure to high altitude (see 
below)[168]. 
 
Studies from lowland dwellers exposed to high altitude have also demonstrated reductions in 
cross-sectional area of muscle fibres.  Hoppeler et al described a 20% reduction in the vastus 
lateralis muscle after 8 weeks [164]. Further, MacDougall et al in the simulated Everest II 
expedition showed 25% and 26% reductions in type II and type I fibre cross-sectional areas 
respectively[163]. A corresponding 9-12% increase in capillary density has also been 
demonstrated however the capillary-to-fibre ratio remains unchanged suggesting this 
increased density is due to the muscle fibre atrophy rather than capillary neo-
formation[159;163;164]. This increased capillary density results in an improved O2 diffusion 
as the same size capillary bed serves a smaller muscle volume which may, in part, compensate 
for the reduction in oxidative capacity. Increased skeletal muscle lipofuscin inclusions were 
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also found after return from high altitude expeditions[169]. Lipofuscin is a mitochondrial 
degradation product and prevails under conditions of high radical formation[170].  
 
Sherpas and Quechas, who have phylogenetic adaptations to altitude, display defence 
mechanisms to hypoxia that have arisen, both independently and by positive selection[171]. 
These include a preponderance of slow type fibres[172;173], a reduction in muscle oxidative 
capacity as measured by mitochondrial density and oxidative enzymes [156;173] and up 
regulation of oxidative rather than glycolytic contributions to metabolism[174]. Kayser et al 
also demonstrated that, despite a low mitochondrial density, Sherpas actually have a higher 
maximal O2- consumption-to-mitochondrial volume than lowland dwellers. Possible reasons 
for this include tighter coupling between ATP supply and demand and better metabolite 
homeostasis[132].  This suggests that, whilst lowlanders do not tolerate spending long times 
at high altitude, native high altitude dweller seem to have adapted allowing them to function 
more successfully in hypoxic environments. 
 
1.6.2 Metabolic Adaptations  
Hypoxia-inducible factor 1(HIF-1) is a key regulator involved in the response to hypoxia in 
most mammalian cells[175]. It is a heterodimer with a dominant α subunit[132]. HIF-1α is 
required for a variety of physiological responses to chronic hypoxia. On exposure to hypoxia 
HIF-1α is rapidly stabilised and accumulates in the nucleus[176;177]. It induces the 
expression of a variety of hypoxia-inducible genes including those that enhance glucose 
metabolism, such as glucose transporters including GLUT-1[178] and glycolytic 
enzymes[179]. Its targets also include  non-metabolic targets including erythropoietin and the 
angiogenic factor VEGF, both of which will increase O2 delivery to tissue through increases 
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in O2 carrying capacity and vascular density[132;180]. Thus, HIF-1α expression may play a 
key role in the adaptation to hypoxaemia in patients with Eisenmenger syndrome which to 
date has not been investigated.  
 
Glucose utilisation is more O2 efficient than fatty acid utilisation in that it produces 6-
6.3moles of ATP per mole of O2 oxidised compared to 5.6mole for fat[181]. Thus, increased 
utilisation of CHO over fats, would aid the maintenance of homeostasis by optimising the 
energy produced per mole of O2.   A switch to an increased reliance on CHO in hypoxic 
conditions would appear to be advantageous and previous work has shown an increased 
reliance on glucose for metabolism both during rest and during exertion after acclimatisation 
to altitude[182-184]. These earlier studies, however, did not consider the possible impact that 
the intensity of the exercise preformed may have. The effect of exercise intensity on substrate 
utilisation is well documented being first reported in 1896 by Chaveau[185] and confirmed in 
1939 by Christensen and Hansen[186].  This led to the suggestion that the switch to an 
increased utilisation of glucose was related to increasing exercise intensity not 
hypoxia[187;188].   
 
In 2002 Lundby et al studied the effect of submaximal exercise, of different intensities, in low 
land dwellers[189]. The initial studies were performed during acute hypoxia and subsequently 
after acclimatisation to >4000m of altitude. Their results show that substrate utilisation, 
during submaximal exercise, is similar during both acute and chronic hypoxia, if the work rate 
is adjusted for the relative sea level maximal VO2 i.e. hypoxia per se does not increase 
carbohydrate utilisation. They concluded that the previous increased CHO oxidation reported 
by others was most likely secondary to higher relative exercise intensity. Similar results were 
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obtained on rats by McClelland et al, who also suggested that the O2 saving advantages of 
CHO is outweighed by limited CHO stores[190].  
 
A difference between sexes was reported by Braun et al in 2000. It is known that at sea-level, 
women show increased preference for lipid metabolism and decreased preference for CHO 
and protein, as compared to men of similar training status[191]. This is due to the metabolic 
regulatory effects of oestrogen and progesterone and is most noticeable in the mid-luteal 
phase.  Braun studied substrate utilisation during sub-maximal exercise in women at an 
altitude of 4300m.  He found that blood glucose utilisation rates were lower at rest but did not 
differ from those recorded at sea-level during sub-maximal exercise [192]. 
 
The adaptations of skeletal muscle in patients with Eisenmenger syndrome have not 
previously been studied. It is feasible though that they have undergone similar adaptations as 
described above which may account, in part, for their known severe exercise intolerance. 
 
1.7 Cardiovascular System and Hypoxia 
1.7.1 Cardiac Adaptations  
Prolonged exposure to hypoxia can trigger cardiovascular defence mechanisms, such as 
increased erythropoiesis and angiogenesis to increase O2 delivery as discussed above. It can 
also promote adaptive cardiac metabolic remodelling[180]. This includes an increased 
reliance in carbohydrates for metabolism and an augmented mitochondria respiratory 
capacity[193]. HIF-1 plays a central role in this switch to increased glucose metabolism in 
cardiac muscle. As indicated above, in hypoxia it becomes stabilised to the heterodimer HIF-
1α that induces the expression of GLUT1 and other glycolytic genes[194]. Alongside this 
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there is also activation of other factors to induce a “fetal gene programme” with increased 
reliance on carbohydrates and a reduction of fat metabolism[180].  Thus, there is increased 
efficiency of energy production and an improved capacity of the mitochondria to sustain 
cardiac contractile function despite hypoxia.  
 
Hypoxia becomes pathophysiological, however, when it exceeds the host organism’s defence 
apparatus. This leads to disruption of the homeostatic balance leading to maladaptive 
signalling cascades and myocardial damage. It is known that hypoxia plays a major role in 
cardiac pathophysiology, including acute coronary syndromes and cor pulmonale.  
 
Myocardial performance in hypoxic environments is dependent on the acclimation state[195] 
with previous biochemical studies on Sherpas showing evidence of increased glucose 
preference by the heart[196]. This was confirmed in an in vivo and non-invasive study using 
cardiac 31P MRS[197]. This showed that the steady state concentration ratio of PCr: ATP was 
maintained at about half that of lowlander hearts. The authors suggested this reflected a shift 
to carbohydrate oxidation to meet the myocardium’s metabolic needs. Holden et al in 1995 
performed positron emission tomography (PET) on high altitude natives (Sherpas and 
Quechuas) and compared the regional cardiac glucose uptake rates to that of sea-level 
residents[196]. They showed that the high altitude dwellers’ hearts have a higher glucose 
uptake in response to the chronic hypoxia. To date no studies have been performed looking at 
the cardiac metabolism in patients with Eisenmenger syndrome. 
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1.7.2 Fetal Circulation  
The fetal circulation is more resistant to hypoxia than the adult heart as it is adapted to the 
relatively hypoxic conditions found in utero[198]. Despite the lower arterial O2 content in the 
fetus compared to the adult, animal studies have shown that the myocardial O2 consumption is 
the same suggesting an increased blood flow and O2 extraction in the fetal circulation[199].  
 
Unlike adult hearts, fetal hearts are more dependent on carbohydrates for metabolism, with a 
decreased capacity to utilise fatty acids[200]. Bartelds et al showed that glucose and lactate 
account for 84% of myocardial O2 consumption in fetal lambs, decreasing to 12% following 
birth[201].  Developmental maturation leads to a shift towards fatty acid oxidation with rapid 
maturation of fat metabolism and increased free fatty acid levels occurring soon after 
birth[198]. However, in hypoxic environments, the neonatal heart remains able to maintain 
anaerobic energy production, thus protecting cardiac function[202].  
 
Patients with Eisenmenger syndrome are not born hypoxic, however they become cyanotic in 
early infancy due to the presence of a large right to left intracardiac shunt. A possible 
mechanism for adaptation to the hypoxaemia is that these patients revert to a fetal form of 
cardiac metabolism with a preference of carbohydrates over fats. 
 
 
1.7.3  Haemodynamic Adaptations  
 
On initial exposure to altitude there is an increase in cardiac output ensuring an adequate 
supply of O2 to tissues[130;131].  This increase is due to a rise in heart rate[203] which in 
turn is predominantly due to activation of the cardiac β-adrenoreceptors by increased levels of 
circulating adrenaline[204]. A reduction in stroke volume, and thus CO, is seen with 
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prolonged exposure to high-altitude but stabilises after 1-2 weeks[130]. The cause of this is 
not fully understood but a reduction in plasma volume[205] and an increased afterload 
secondary to sympathetic driven elevated systemic vascular resistance are likely to 
contribute[131].  
 
Previous studies have demonstrated that the sympathetic nervous system (SNS) is activated 
during both acute and chronic exposure to high altitude, with acclimatisation being 
accompanied by maintained sympathoexcitation[130;206]. Mazzeo et al demonstrated a 
significantly increased muscle sympathetic activity, as measured by elevated plasma 
noradrenaline levels, both at rest and during submaximal exercise in individuals exposed to 
chronic high altitude[153].  Hansen et al measured sympathetic response directly using 
peroneal microneurography and showed an increased response in acclimatised 
individuals[206]. Interestingly they also showed that the elimination of the chemoreflex by 
supplemental O2 and the baroreflex with additional saline had little effect on the increased 
SNS response, thus the major underlying mechanisms remain unexplained. The lower 
maximal heart rate despite the elevated catecholamine levels suggests a down-regulation of 
the β-adrenoreceptors. This was confirmed by Voelkel et al in 1981 who demonstrated a 
halving in density of β-adrenoreceptors in rats after five weeks at a simulated altitude of 
4250m[207]. 
 
1.8 Adaptations to Hypoxaemia in Eisenmenger Syndrome 
As discussed above, the adaptations to the chronic and severe hypoxaemia found in 
Eisenmenger syndrome have not previously been investigated. A further understanding to 
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these adaptations may help us in the future to develop new therapeutic strategies in managing 
patients with hypoxaemia from other causes, such as those acutely unwell on Intensive Care. 
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Table 1.1. Causes and frequency of Eisenmenger syndrome (adapted from Wood 
[4]) 
 
Anatomical abnormality Frequency of Eisenmenger reaction 
(%) 
PDA 
AP window 
Truncus arteriosus 
TGA with VSD 
Corrected TGA with VSD 
Single ventricle 
VSD 
Common AV canal or persistent ostium primum 
Single atrium 
ASD 
Hemianomalous pulmonary venous drainage 
Total anomalous pulmonary venous drainage 
16 
60 
100 
58 
100 
100 
16 
43 
None seen in series 
6 
0 
17 
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Table 1.2 Classification of PAH associated with congenital heart disease 
(adapted from Diller at al [5]) 
 
Type of lesion 
 
Lesion dimensions 
 
 
Associated extracardiac anomalies 
Repair status 
 
 
Simple 
Complex 
Small to moderate (ASD ≤ 2cm. VSD & PDA 
≤ 1cm) 
Large (ASD >2cm, VSD & PDA >1cm) 
 
Unoperated 
Palliated 
Repaired 
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Appendix 1.1  Ability Index questionnaire (adapted from Warnes et al[17] 
 
Ability Index 1 Normal life and full-time work or in school 
Ability Index 2 Able to work, with intermittent symptoms, interference with daily life 
(socio / community impositions because of cardiac anomaly) 
Ability Index 3 Unable to work and limited in all activities 
Ability Index 4 Extreme limitation, dependent, almost housebound 
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Figure 1.1 Generation of ATP in the mitochondria 
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Figure 1.2 Generation of ATP during muscle fibre contraction 
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2. Objectives  
 
The primary objective of this work was to investigate how the patient with Eisenmenger 
syndrome has adapted physiologically to a life time of severe hypoxaemia and pulmonary 
hypertension. Our aim was to gain an understanding of how these patients manage to  
function relatively well and have better than expected survival despite these adverse factors. 
A greater understanding of how these adaptive changes have conferred protection in these 
patients may, in the future, be applied in other hypoxic patients who do less well. They may 
also serve as potential targets for future therapeutic strategies.   
 
2.1 Hypotheses 
1. Patients with Eisenmenger syndrome have severe exercise intolerance with an early 
shift to anaerobic metabolism. 
 
2. There are alterations in skeletal muscle mitochondrial metabolism to account for the 
exercise intolerance, as assessed by the PCr recovery. 
 
3. They have maintained cardiac systolic function but right ventricular diastolic 
dysfunction as measured by echocardiography.  
 
4. There is preservation of the septal energetics allowing maintenance of the contractile 
function.  
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2.2 Patient Selection 
Patients with Eisenmenger syndrome under the care of the Adult Congenital Heart Disease 
unit at the Queen Elizabeth hospital, Birmingham, were invited to participate in this study. 
Patients with any diagnosis listed in table 1.1 were included. Patents who had undergone 
previous cardiac surgery were excluded. Patients were also excluded if they had limiting 
musculoskeletal abnormalities or peripheral vascular disease, or if they were unable to give 
informed consent. This included patients with co-existent Downs’s syndrome which excluded 
approximately half of our Eisenmenger population. Patients were required to be clinically 
stable with no deterioration in the previous three months.  
 
Healthy controls who were age and sex matched to our patients were recruited. They were 
excluded if they had limiting musculoskeletal abnormalities or peripheral vascular disease and 
must have no history of cardiac or other systemic illness. 
 
2. 3 Experimental Studies 
We performed a series of non-invasive clinical studies looking at four specific areas as 
outlined below in section 2.4. Studies were carried out in the department of Cardiovascular 
Medicine research department, Queen Elizabeth hospital, Birmingham. The MRI scans were 
performed in the Birmingham University Imaging Centre. Ethical approval for the study was 
obtained from the Warwickshire Local Research Ethics Committee. 
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2.4 Questions Investigated 
2.4.1 Exercise 
As discussed in section 1.2, patients with Eisenmenger syndrome have severe exercise 
intolerance when measured objectively. We therefore investigated this intolerance in greater 
detail with the aim of identifying the factors that limits exercise by examining the 
cardiorespiratory response to exercise and the VO2 kinetics using cardiopulmonary exercise 
testing. 
 
2.4.2 Skeletal Muscle Adaptations 
In addition, we used 31P MR spectroscopy to investigate skeletal muscle energetics in patients 
with Eisenmenger syndrome, specifically the PCr recovery time, and compared them with our 
healthy control subjects. We have also examined the pH drop in the exercising muscle to gain 
further insight into the balance of aerobic vs anaerobic metabolism in severe hypoxaemia. In a 
subset of patients we assessed the resting O2 consumption of skeletal muscle by using near 
infra-red spectroscopy with the aim of establishing whether this differs in the setting of severe 
hypoxaemia. Finally, we investigated peripheral fatigue and the substances linked to it in 
Eisenmenger syndrome to assess whether they are affected by a low PO2. 
 
2.4.3 Cardiac Function 
We performed transthoracic echocardiography to investigate the ventricular function in 
Eisenmenger syndrome. As the interventricular septum is known to have an increased 
importance in pulmonary hypertension, we specifically investigated its role as well as the 
interaction between the ventricles in presence of a large intracardiac shunt. Whilst previous 
studies have demonstrated that systolic function is relatively preserved in Eisenmenger, no 
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study to date has investigated diastolic function thus this was assessed in the left and right 
ventricles. 
 
2.4.4 Cardiac Energetics 
We used 31P MR spectroscopy to investigate the energetics of the interventricular septum in 
Eisenmenger syndrome. We then examined whether there are correlations between this and 
echo parameters in order to investigate whether abnormalities in the energetics precede 
contractile dysfunction. 
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3. INVESTIGATION OF THE FACTORS RESPONSIBLE FOR 
EXERCISE LIMITATION IN EISENMENGER SYNDROME 
 
3.1 Introduction 
3.1.1 Cardiopulmonary Exercise Testing 
Cardiopulmonary exercise testing (CPET) offers significant advantages over conventional 
methods of assessing performance, as it provides an integrated assessment of 
cardiopulmonary function and reflects underlying metabolic processes[208]. In doing so it 
assesses O2 delivery, via the lungs, O2 transport via the cardiovascular system, and O2 uptake 
by the end organ, with further information being obtained by the analysis of CO2 production. 
It is an objective and reproducible approach for determining true functional capacity by 
combining both performance and physiological parameters to underlying metabolic 
processes[209;209]. It can be used to assess the response to both submaximal and maximal 
exercise and provides prognostic information[210;211].   
 
CPET directly measures O2 uptake (VO2), CO2   production (VCO2) and airflow (minute 
volume, tidal volume and respiratory rate) using a non-breathing valve attached to a metabolic 
cart. From these measurements, other clinically relevant parameters may be derived.  
 
Exercise capacity is determined by gas exchange within the lungs, cardiovascular 
performance and skeletal muscle metabolism[212].  
 
The foundation of the studies described in this chapter was that patients with Eisenmenger 
syndrome may have abnormalities of any of these and the use of CPET may allow us to 
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establish the predominant limiting factor. The discussion below considers some of the issues 
we particularly wished to address. 
 
3.1.2 Oxygen Uptake  
Oxygen uptake (VO2) occurs at the alveoli in proportion to the pulmonary blood flow and the 
O2 saturation of the haemoglobin in the pulmonary capillary blood[213]. The VO2 is the 
product of cardiac output and the O2 content differential between pulmonary artery and vein 
and is defined by the Fick equation:  
VO2   = (SV x HR) x (CaO2 – CvO2)  
It is determined by the maximum cardiac output, arterial oxygen content, fractional 
distribution of the cardiac output to skeletal muscle and the ability of muscle to extract 
oxygen.  Muscle extraction of oxygen is dependent on oxygen delivery and peripheral 
circulatory factors such as muscle capillary density, mitochondrial density and oxidative 
enzyme levels (as discussed in section 1.5.4).   
 
The VO2 plateaus as one of the above determinants approaches its threshold. The maximal 
VO2 (mVO2)  was originally defined as “the VO2  at which performance of increasing levels of 
constant work fails to increase VO2 by 150ml/min despite increasing work rate”[214]. As 
150ml/min is a significant fraction of that obtained by some patients, it may also be 
determined by observing that the VO2 fails to increase normally relative to an increase work 
rate just prior to fatigue[213]. This plateau may not be achieved by some subjects prior to 
symptom limitation and the peak VO2 (pVO2) is then used, defined as “the highest VO2  
averaged over a 20-30 second period at maximal effort”[209].  For this study we will refer to 
pVO2. 
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Reduced VO2 is seen in many acquired cardiovascular diseases including chronic heart failure 
and has been shown to be associated with a poor outcome[105;210;215;216]. Diller et al 
studied pVO2 in cohorts of patients with congenital heart disease, again showing that a low 
pVO2 is associated with poor clinical outcomes[24].  
 
3.1.3 Ventilatory Efficiency 
Ventilatory efficiency, as measured by the VE/VCO2 slope, is a measurement of the amount 
of air required to eliminate 1 litre of CO2. A high VE/VCO2 slope has again been shown to be  
associated with a worse outcome, with higher rates of hospitalisation and mortality, in both 
patients with acquired heart failure[210;211;217] and non-cyanotic cardiac defects[26]. 
However,  this did not hold for patients with cyanotic congenital heart disease[26].  
 
3.1.4 Anaerobic Threshold 
Exercise capacity can also be estimated using the anaerobic threshold (AT), an index that is 
independent of motivation.  It is defined as “the VO2 during exercise at which aerobic energy 
production is supplemented by anaerobic mechanisms such that it is reflected by an increase 
in lactate concentration”[218].  A reduced AT of <40% of the predicted peak VO2 is 
considered abnormal and is suggestive of cardiovascular disease[219].  
 
There are two main methods of estimating the VO2AT using CPET[212].  In the V-slope 
method, the AT occurs when the VCO2 accelerates relative to VO2[212] (figure 3.1a). The 
ventilatory equivalent method defines the AT as “the VO2 at which the ventilatory equivalent 
for O2 (VE/VO2) begin to increase without an immediate increase in the ventilatory equivalent 
for CO2 (VE/VCO2)”[212](figure 2.1b). However, the use of CPEX to assess the AT is open 
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to considerable inter- and intraobserver variability[220], therefore in this study we used both 
methods. 
 
3.1.5 Respiratory Exchange Ratio 
The respiratory exchange ratio (RER) is the ratio of CO2 produced and O2 consumed and 
equals the respiratory quotient in the steady state[212]. It is often used as a marker of effort 
with a peak RER <1.1suggesting submaximal exercise[209;219].Patients with cyanotic 
congenital heart disease have been shown to achieve a significantly lower RER than non-
cyanotic patients[24;26] and it was suggested that the usual benchmarks for interpreting gas 
exchange in this group may not have the same meaning. [26].  
 
3.1.6 Oxygen Uptake Efficiency Slope 
The oxygen uptake efficiency slope (OUES) is a further method used to assess exercise 
capacity and is a measurement of the relationship between the VO2 and a given VE during 
exercise, that is the efficiency by which the body takes in and then extracts O2 [209]. It is  
calculated by the following equation where “a” is the OUES and “b” the intercept (figure 
2.2)[221]: 
   VO2 = a log10VE + b 
 
Whilst mVO2 and VE/VCO2 slope are both effort-dependent and may not be accurate for 
submaximal exercise, the OUES uses the whole exercise data and is thus useful in patients 
who only complete a submaximal test[222]. Hollenberg et al demonstrated that there was only 
a 1.9% difference in the OUES calculated during the first 75% of exercise data from the data 
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obtained from the complete test in patients with CHF[223].  It is also highly reproducible with 
low interprotocol variability[224]. 
 
 OUES has been shown to be significantly reduced (indicating greater ventilatory effort for a 
given VO2) in patients with CHF[222;224] and significant coronary artery disease coronary 
artery[225]. Like mVO2 and VE/VCO2 slope it has also been shown to be a powerful 
prognostic marker in CHF. Giardini et al has looked at the accuracy of the OUES in adults 
with congenital heart disease[226]. He noted that in cyanotic patients with a Fontan 
circulation, the OUES at 50% maximal exercise capacity (OUES50) was different to that over 
the second half of exercise.  However it is not clear whether this was due to the cyanosis or 
the abnormal haemodynamics found in Fontan patients. One study has looked at the effect of 
acute hypoxia on the OUES showing that there was no difference in the OUES100 or OUES80 
and concluded that is an accurate submaximal index to assess cardiorespiratory fitness in 
patients with arterial hypoxaemia[227].  To date no studies have specifically examined the 
OUES in patients with Eisenmenger syndrome.  
 
3.1.7 The Exercise Paradox in Eisenmenger Syndrome 
In patients with Eisenmenger syndrome there appears to be a profound paradox between the 
objective exercise indices, as demonstrated in previous studies, and patient survival and 
functional ability[16;24;26]. The true cause of the exercise limitation is not fully understood 
and likely to be multifactorial. Therefore the primary aim of the studies described below was 
to investigate the cause of the exercise limitation in this patient group.  
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3.2 Methods 
3.2.1 Subjects 
Nine patients with Eisenmenger syndrome and 8 age and sex matched healthy volunteers 
(HV) underwent a symptom –limited erect treadmill test in the department of Cardiovascular 
Medicine, University of Birmingham. Prior to exercise the functional class of all subjects was 
assessed by ability index[17] and Borg dyspnoea score[228] 
 
3.2.2 Monitoring and Equipment 
A face mask was fitted tightly to cover mouth and nose and ensuring no air leak.  The mask 
was attached to a non-breathing valve to prevent mixing of inspired and expired air. 
Simultaneous gas analysis was performed throughout exercise with a Schiller CS-200 Ergo-
Spiro exercise machine. Blood pressure, ECG and oxygen saturations were monitored 
throughout exercise and for 5 minutes of recovery using an automatic sphygmanometer, ECG 
cables and pulse oximeter all connected through the exercise machine.  
 
3.2.3 Protocol 
A standardised ramp protocol was used as previously described[229]. In brief, this uses 
simultaneous increases in speed and inclines to produce a ramp-wise increase in work rate. 
The “Ramp 2” protocol begins with a belt speed of 1km/h and an incline of 1%. It then 
increases each minute by 1km/h and 1% inclines. A “ramp 1” protocol was used in subjects 
with self-reported poor exercise tolerance.  This starts at 0.5km/h at 0.5% and increases by 
0.5km/h and 0.5% at one minute intervals. 
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Exercise was preceded by a resting period of at least five minutes to allow steady state 
gaseous exchange to be reached.  During this time the resting VO2, VE, O2 pulse and HR 
were calculated as the mean value during the last minute prior to exercise starting.   
 
All subjects were encouraged to continue until fatigued.  Medical reasons to terminate the test 
were as per the ACC/AHA guidelines for exercise testing[230].  Reason for stopping was 
recorded for each subject. 
 
3.2.4 Data Analysis 
Directly measured variables were VO2, VCO2, minute ventilation (VE), respiratory rate and 
heart rate.  Directly calculated from these values were RER (VCO2/VO2) and O2 pulse 
(VO2/HR) which gives an estimate of stroke volume[209]. After completion of the test the 
data was transferred to a Microsoft Excel programme for off-line analysis. The pVO2, 
VE/VCO2 slope, and OUES were calculated as previously described[210;213;222]. The AT 
was assessed by both V-slope method and ventilatory equivalent methods and expressed as an 
average of both. The breathing reserve relates the ventilatory response during maximal 
exercise to the maximal ability to breathe and is estimated by the ratio of the maximal VE and 
maximal voluntary ventilation (MVV). 
.  
3.2.5 Statistical Analysis 
Continuous data are expressed as mean ± SEM.  The data was normally distributed, as 
determined by Kolmogorov-Smirnov test of normality, and thus groups were compared using 
independent-samples t-test. A p<0.05 was taken as being statistically significant. All 
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statistical operations in this and subsequent chapters were performed using SPSS (version 
15.0. SPSS Inc, Chicago, Illinois). 
 
3.3 Results 
3.3.1 Baseline Data 
Nine subjects (six female) with Eisenmenger syndrome aged 31-50 years (mean 42 years) 
underwent CPET.  Their individual underlying diagnoses are presented in table 2.1. Two 
patients were on bosentan and one on sildenafil. Their mean haemoglobin was 20.4 ± 1.4g/dl 
with baseline oxygen saturations of 79.7 ± 2.1%.  The ability score was I in three patients, II 
in five patients and III in one patient. Three patients were in full time employment, one in part 
time and five not working (one of whom had recently retired).  Their mean Borg dyspnoea 
score at rest was two. All patients were in sinus rhythm during this study and had a normally 
reactive heart rate.  
 
The control group consisted of eight healthy volunteers (six female) aged 33-53 years (mean 
42years). All controls were free from cardiovascular, pulmonary or other systemic disease.  
Trained athletes were excluded. Their mean haemoglobin was 14.2 ± 1.2 with baseline 
oxygen saturations of 98.3 ± 0.3%.  The ability index was I in all control subjects and all were 
in full time employment.  Mean Borg score at rest was one.  
 
All eight control subjects exercised using the ramp 2 protocol.  Four of them stated shortness 
of breath as the reason for terminating exercise and four were unable to keep with the speed 
and incline.  Only two of the patients with Eisenmenger syndrome attempted ramp 2 with the 
other seven using ramp one. All nine patients stated shortness of breath as their reason to stop. 
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3.3.2 Resting Data 
There was no difference in the resting O2 consumption (VO2) between healthy controls (0.38 
± 0.03ml/kg/min) and patients (0.33 ± 0.02 ml/kg/min, p = 0.2).  Resting O2 pulse, as an index 
of stroke volume, was also similar in controls and patients (4.2 ± 0.4ml/beat and 3.9 ± 0.3 
ml/beat, p = 0.42). 
 
3.3.3 Exercise Data 
The mean pVO2 was significantly lower in patients with Eisenmenger syndrome (13.2 ± 
1.2ml/lg/min) than in the healthy controls (37.3 ± 2.1ml/kg/min, p < 0.001) (figure 2.3).  The 
VE/VCO2 slope was higher in patients (54.2 ± 2.8) compared to the controls (29.8 ± 1.1, p < 
0.001) (figure 2.4).  The OUES was also lower in the Eisenmenger patients (1.0 ± 0.4l/min) 
compared to the healthy controls (2.7 ± 0.8l/min, p < 0.001) (figure 2.5).  
During exercise the patient group achieved a lower maximum heart rate than controls (132 ± 
6.8 vs 179 ± 4.6, P < 0.05) despite there being no difference in resting heart rate (85.4±3.7 vs 
91.1 ± 7.1, p = 0.47).  The O2 pulse at peak exercise within the patient group was lower at 
peak exercise compared to the controls (6.7 ± 0.7 ml/beat vs 16.7 ± 1.3 ml/beat, p < 0.001).  
 
3.3.4 RER and Anaerobic Threshold 
Only 3 in the patient group reached an RER > 1.0 despite exercising to exhaustion, whereas 
all control subjects did.  The control group had a significantly higher AT compared to the 
Eisenmenger group (23.0 ± 3.8 vs 12.5 ± 3.4ml/kg/min, p<0.01), however 3 Eisenmenger 
patients again did not reach their AT. When expressed as a percentage of maximum exercise, 
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the patients with Eisenmenger syndrome reached their AT at a later stage in exercise than the 
healthy controls did. 
 
3.3.5 Ventilatory Response to Exercise 
Patients with Eisenmenger syndrome had a significantly higher resting ventilation, as 
measured by minute volume (VE), compared to healthy controls (13.7 ± 0.6l/min vs 11.4 ± 
0.8l/min, p <0.05). However, during exercise they achieved much lower peak VEs (48.3 ± 7.5 
l/min vs 80.5 ± 6.4 l/min, p < 0.05) and lower maximal respiratory rates (38.5 ± 4.3 vs 46.5 ± 
2.3, p<0.05).  Both groups had normal breathing reserves indicating that they were not limited 
by restrictive or obstructive airway disease.  The breathing reserve was actually significantly 
higher in the patient group (68 ± 5.7%) than in the healthy controls (36.8 ± 7.1%, p < 0.05).   
 
3.4 Discussion 
Whilst other groups have looked at the exercise capacity of patients with cyanotic heart 
disease, they have included only small proportion of patients with Eisenmenger syndrome. 
Cyanotic congenital heart disease includes a very heterogeneous group of patients whose 
haemodynamic response to exercise will vary between patients depending on the underlying 
diagnosis and physiology. Whilst our numbers are also small, our study is the first study to 
look solely at adult patients with Eisenmenger syndrome. 
 
Patients with Eisenmenger syndrome have severely limited exercise capacity as shown by a 
markedly impaired pVO2 compared to age matched healthy control subjects. The pVO2 can be 
decreased by either decreased O2 utilisation by the cells or reduced supply of O2 to active 
tissue. Whilst CPET does not give specific information regarding the former, information 
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regarding the latter can be determined. We have documented a reduction in peak VE, 
respiratory rate, heart rate and O2 pulse during maximal exercise in patients with Eisenmenger 
syndrome; all of which would be expected to lead to impaired supply of O2 to the tissues. 
 
In our study patients with Eisenmenger syndrome had a similar resting VO2 to healthy 
controls.  This differs from the findings of Theodore at al who documented that their resting 
VO2, measured invasively, was actually double that of normal subjects[21].  They attributed 
this increase to the increase cardiac work and work of breathing.  They also noted that the 
patients could increase their VO2 to approximately double the resting value during exercise. 
They hypothesised that this indicates that the basic mitochondrial function is not impaired 
despite the profound hypoxaemia in Eisenmenger syndrome.  
 
Despite having higher resting ventilation than healthy controls, their VEs and respiratory rates 
at peak exercise were significantly lower. However, previous studies investigating the effects 
of hypoxia during exercise have shown that ventilation increases with decreasing arterial 
PaO2 due to the hypoxic ventilatory drive mediated by peripheral chemoreceptors[135]. 
Patients with Eisenmenger syndrome therefore appear to have acclimatised to the severe 
hypoxaemia present from an early age and it is possible that their hypoxic ventilatory drive 
may be suppressed, similar to that of native high altitude dwellers. However, all patients in 
this study stated severe shortness of breath as the reason for terminating exercise. One reason 
may be that they are unused to exerting themselves to this degree.  Another may be alterations 
in their perception of breathless due to the longstanding severe hypoxaemia. 
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Our patients have a markedly abnormal ventilatory efficiency during exercise as shown by 
elevated VE/VCO2 slopes. A decreased ventilatory efficiency in patients with Eisenmenger 
syndrome and other cyanotic heart disease has been demonstrated previously[26]  and 
correlates well to the degree of cyanosis and thus size of shunt[231]. This inefficiency is due 
to both the increase in physiological dead space and alveolar hypoventilation. During exercise 
the right to left shunt increases, with up to 60% of the cardiac output not being exposed to 
alveolar gas exchange during exercise. This leads to pulmonary hypoperfusion, VQ 
mismatching and an increase in physiological dead space[26]. The dependence of ventilatory 
efficiency and physiological dead space has also been reported in CHF and idiopathic 
pulmonary hypertension[232;233]. In these conditions the increase in right to left shunting 
also leads to alveolar hyperventilation, reflected by alveolar hypocapnia, in order to normalise 
the systemic PaCO2[234].    
 
A further contributory factor to the ventilatory inefficiency may be the severe pulmonary 
hypertension present in Eisenmenger syndrome. A high VE/VCO2 slope has also been 
demonstrated in other causes of pulmonary hypertension (PHT) including idiopathic 
PHT[235], congestive cardiac failure complicated by PHT[236] and COPD associated with 
PHT[237].  Lewis et al have demonstrated a significant correlation between VE/VCO2 slope 
and both exercise PVR and poor RV performance[236]. Furthermore they showed that the 
administration of sildenafil, a selective pulmonary vasodilator, for 12 weeks significantly 
reduced the VE/VCO2 slope.  In our study, only three patients were taking selective 
pulmonary vasodilators thus it is not possible to assess for a difference within our group.  
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We also demonstrated an abnormal ventilatory response to exercise using OUES.  Our results 
show that patients with Eisenmenger syndrome had markedly low OUES compared to the 
control group, indicating that increased ventilatory effort was required for a given VO2. This 
study is the first to use OUES as a measure of ventilatory response to exercise in this group of 
patients. It has previously been shown, in other groups of patients, to be a non-effort 
dependent and useful submaximal index of cardiorespiratory reserve.  The effect of hypoxia 
on the OUES was investigated by Mollard et al who investigated the response of the OUES to 
hypoxia by exercising both trained and untrained subjects at increasing levels of simulated 
altitudes[227]. They found no difference between the OUES80 and OUES100 and that the 
OUES80 was influenced to the same extent as the peak VO2 during exercise performed in 
hypoxia.  Thus, OUES could be considered a reasonable sub-maximal index in patients with 
arterial hypoxaemia such as those with Eisenmenger syndrome.  
 
In our study 3 patients with Eisenmenger syndrome failed to reach their anaerobic threshold 
(AT). As discussed above in section 2.1.4 there are two methods of assessing the anaerobic 
threshold; the V-slope method and the ventilatory equivalent method.  Glaser et al determined 
the VO2AT in 25 patients with cyanotic congenital heart disease, including five with 
Eisenmenger syndrome[231] and found that  they were unable to accurately determine the 
VO2AT in almost one third of patients using the V-slope method and they comment that it 
was not clear if these patients really did not reach AT or if it was obscured by alterations in 
their ventilatory patterns. As measurement of AT by the V slope method assumes a strictly 
CO2-controlled ventilatory drive and these patients may have a significant hypoxic 
contribution to ventilatory controls, they conclude that the V slope method may not be 
appropriate in this cohort.  However, in our study we used both methods and used the average 
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of the two. In those patients who appeared not to reach their AT we were unable to measure it 
by either method. 
 
In the present study, the patients with Eisenmenger syndrome who did reach their AT did so 
at a relatively later stage in exercise, as measured by percentage of maximal exercise, than 
healthy controls. A similar finding was made by Sun et al who investigated the exercise 
response of patients with primary PHT and showed that AT becomes a higher fraction of peak 
VO2 as disease severity increases[235]. They suggested that this reflects a decreasing 
cardiovascular reserve as PHT worsens.  Conversely Glaser et al report that patients with 
cyanotic heart disease in their study showed early anaerobic metabolism [231]. However, his 
cohort of 27 patients only included 5 with Eisenmenger syndrome thus other factors, such as 
single ventricle physiology, may have contributed to their result.   
 
On the other hand, Theodore et al examined the venous lactate concentrations during exercise 
in patients with Eisenmenger syndrome[21]. They noted that the increase in lactate levels 
during exercise were modest and suggested that the term “anaerobic threshold” is not 
appropriate for these patients who function above an AT during the course of normal activity. 
 
In conclusion, patients with Eisenmenger syndrome have severely impaired exercise tolerance 
with marked ventilatory inefficiency. Despite this they appear to have a reliance on aerobic 
pathways as evidenced by reaching their anaerobic threshold late in their exercise or not 
reaching it at all. Further information regarding the energetic status of the exercising skeletal 
muscle using31P MRS may give further insight into the mechanism of the exercise 
intolerance. 
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Figure 3.1a Original graph demonstrating the V-slope method of determining anaerobic 
threshold. The y-axes plot the VO2 (blue line) and VCO2 (red line) during 
exercise against the duration of exercise eon the x-axis. The anaerobic 
threshold (AT) is calculated from the point the VCO2 increases relative to the 
VO2. 
 
 
 
 
 
 
 
Figure 3.1b Original graph demonstrating the ventilatory equivalent method for 
determining anaerobic threshold. The y-axes show the ventilatory equivalents for O2 
(VE/VO2, blue line) and CO2 (VE/VCO2, red line) and the x-axis plots the exercise time. The 
anaerobic threshold is the VO2 at which the EQO2 increases without an increase in ECO2.
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Figure 3.2 An example of the oxygen uptake efficiency slope of a healthy control subject. The y-axis shows 
the VO2 in ml/kg/min and the x-axis shows logVE in l/min 
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Figure 3.3 Comparison of pVO2 in healthy controls and Eisenmenger 
patients. Each column shows mean ± SEM; ***: P<0.001  
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Figure 3.4 Comparison of VE/VCO2 in healthy controls and Eisenmenger 
patients. Each column shows mean ± SEM; ***: P<0.001   
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Figure 3.5 Comparison of OUES in healthy controls and Eisenmenger 
patients. Each column shows mean ± SEM; ***: P<0.001 
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 Age (y) Underlying cardiac defect 
1 50 VSD 
2 41 VSD 
3 42 VSD, PDA 
4 49 VSD 
5 50 VSD 
6 48 VSD 
7 31 VSD 
8 38 AVSD 
9 38 ASD 
 
 
Table 3.1 Characteristics of patients with Eisenmenger syndrome 
 
VSD = ventricular septal defect, PDA = patent ductus arteriosus, AVSD = atrioventricular 
septal defect, ASD = atrial septal defect 
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4. INVESTIGATION OF SKELETAL MUSCLE ADAPTATIONS IN 
PATIENTS WITH EISENMENGER SYNDROME  
 
4.1 Introduction 
As indicated in the introduction, very little is known of skeletal muscle energetics or 
mechanisms underlying fatigue in patients with Eisenmenger syndrome. Thus, in the present 
studies, 31P MRS was used as means of following high energy phosphates, PCr and pH during 
and following exercise and NIRS was used as way of following tissue oxygenation. In 
addition, separate studies were performed to assess venous efflux of some of the substances 
that may be involved in fatigue. The discussion below provides the background to these 
studies.  
4.1.1 Basis of MRS  
Magnetic resonance spectroscopy (MRS) provides metabolic information from nuclei with 
magnetic spin including 31P, 13C, 1H and 123Na, each nucleus type having a characteristic 
frequency when placed in the same magnetic field[238]. This technique allows non-invasive 
assessment of the biochemical composition and metabolic changes of tissue without the need 
for a tracer.  
 
A radiofrequency (rf) pulse, emitted from a surface coil, causes spin excitation of the nuclei 
followed by relaxation when the rf pulse is switched off. This results in a MR signal, termed 
the free induction decay, which is then subjected to Fourier transformation into a frequency 
domain spectrum[238;239].  The resonance frequency of the individual nuclei, termed the 
chemical shift, allows the differentiation of single metabolites within one molecule[240].  
Once correction factors have been applied, the area under each spectral peak is directly 
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proportional to the metabolite’s relative concentration[239]. Of note, the spectrum obtained 
gives the concentrations of metabolites relative to each other, expressed as parts per million 
(ppm), not absolute concentrations. 
 
4.1.2 Skeletal Muscle   31P MRS 
31P MRS allows the non-invasive assessment of skeletal muscle high energy phosphate use in 
vivo.  In normal skeletal muscle, there are peaks for PCr, Pi and the 3 types of ATP (γ, α and 
β), thus their relative concentrations may be determined.  ADP concentration cannot be 
quantified as it is predominantly protein bound and thus free concentrations are too low to be 
detected[77]. 
 
4.1.3  Skeletal Muscle   31P MRS and Exercise   
As discussed in section 1.4.2, high energy phosphate molecules are important in both cellular 
energy and storage, with ATP providing the energy for muscle contraction. However, whilst 
muscle performance and O2 consumption can vary greatly, ATP levels remain virtually 
constant[241]. ATP levels are maintained during exercise by hydrolysis of PCr, oxidative 
phosphorylation and anaerobic glycogenolysis. 
 
PCr hydrolysis occurs 10 times quicker than oxidative phosphorylation and therefore 
represents most important initial energy source in skeletal muscle at at the start of 
exercise[77;241].  PCr is dephosphorylated by the following equation: 
PCr + ADP + H+         ATP + Creatine 
 
CK 
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High energy phosphate metabolism within skeletal muscle during exercise and recovery from 
exercise can be measured using 31P MRS[242]. The rate of PCr recovery following the 
cessation of exercise closely reflects mitochondrial oxidative capacity[77]. Submaximal 
exercise is associated with low levels of stress and thus it may be more appropriate in those 
subjects unused to more strenuous activity[243].  
 
31P MRS may also be used to calculate intracellular pH within the exercising skeletal muscle. 
The ionisation constant (pKa) of PCr is significantly different from physiological pH and thus 
the PCr peak on the spectrum differs little throughout exercise and recovery[77]. The pKa of 
Pi however is approximately equal to its pH and its position on the spectrum, therefore, is pH 
dependent. The difference between the two peaks is termed the chemical shift and this can be 
used to determine pH using the following equation[242]: 
 pH = 6.75 + log10[(δPi – 3.27) / (5.69 – δPi) 
 
4.1.4 31P MRS and PCr Recovery Following Exercise     
At the end of exercise glycolysis is switched off and studies have shown that no metabolic 
recovery is seen if the muscle is made ischaemic at the end of exercise[61;244] with 
resynthesis only occurring if there is an intact blood supply[245;246]. Recovery is therefore 
entirely oxidative and the use of 31P MRS  to assess the PCr recovery following exercise, has 
been recognised as a valuable and reliable method in the quantification of  the rate of 
oxidative ATP production in intact muscle [60;61;74;244;247].   
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This method of measuring skeletal muscle oxidative capacity is useful as it is independent of 
the intensity of exercise, provided that pH does not fall severely[61;248] and also for active 
muscle mass[249].  
    
4.1.5 PCr Recovery in Other Disease States and  Hypoxia 
The use of 31P MRS to measure PCr recovery does not discern between limitations caused by 
O2 supply from that of mitochondrial demand. Thus, Haseler et al have shown that in 
sedentary subjects, it is the  mitochondrial capacity and not O2 availability that determines the 
maximal oxidative rate [250]. On the other hand, they have also demonstrated that PCr 
recovery is prolonged in severe hypoxia due to the decreased availability of O2, whilst in 
normoxia and moderate hypoxia the maximal oxidative rate is dependent on training 
status[243]. They conclude that until the O2 levels fall well below that of normal air, the O2 
availability does not affect the maximal oxidative rate in sedentary subjects. 
 
Interestingly, PCr recovery has also been shown to be prolonged in some disease states 
characterised by impaired O2 delivery to the skeletal muscle, either by reduced flow or 
hypoxaemia. These include COPD, CHF, diabetes mellitus and peripheral vascular 
disease[113;251-253].  
 
Only two studies have previously used 31P MRS to investigate skeletal muscle energetics in 
congenital heart disease. Miall-Allen et al studied children and found a non-significantly 
prolonged PCr recovery in cyanotic children when compared to those with acyanotic 
conditions[254].  Adatia et al studied 10 subjects, median age 17.3years, with cyanotic 
congenital heart disease[255].  They found that the PCr recovery time was 2-3 times longer 
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than in healthy control subjects. They also describe a greater PCr depletion during exercise 
and a bigger fall in pH. Both of these groups commented on a higher resting pH in cyanotic 
patients that correlated with Hb concentration.  
 
To date no study has investigated the skeletal muscle energetics in adults with Eisenmenger 
syndrome. Thus, it is not known whether a reduced skeletal muscle oxidative capacity 
secondary to the severe hypoxaemia, a decreased rate of oxidative metabolism or even a 
sedentary lifestyle, contributes to the known exercise limitation seen in these patients. 
 
4.1.6 Assessment of Tissue Oxygenation 
Unlike 31P MRS, near-infrared spectroscopy (NIRS) is able to discern the limitation caused by 
O2 supply rather than that of mitochondrial demand. NIRS is a non-invasive and continuous 
technique that measures tissue oxygenation in skeletal muscle. It can be used to estimate the 
concentrations of oxy- (oxy-Hb), deoxy- (deoxy-Hb) and total haemoglobin (HbT) within the 
region being investigated.  
 
In the absence of blood flow, for example during arterial occlusion, the O2 is consumed by the 
mitochondria thus its content within the tissue will decrease as it.  Therefore O2 consumption, 
which reflects resting muscle metabolic rate, can be assessed by the reduction in oxy-Hb 
during arterial occlusion, providing the duration of occlusion does not allow a significant shift 
to anaerobic metabolism.  
 
NIRS has been used to demonstrate abnormal tissue oxygenation due to insufficient delivery 
in several conditions associated with skeletal muscle abnormalities including CHF[256], 
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peripheral vascular disease[257] and diabetes mellitus[253]. To date, skeletal muscle NIRS 
has not been used in cyanotic congenital heart disease to investigate tissue oxygenation 
abnormalities. 
 
4.1.7 Fatigue 
Early skeletal muscle fatigue during exercise has been demonstrated to be one cause of 
exercise intolerance in patients with CHF and is due to intrinsic muscle factors rather than 
cardiac reserve or central control[258].  It has also been shown to occur in patients with 
hypoxaemia secondary to COPD[259].   
 
As discussed in section 1.4.5 peripheral fatigue is mediated by metabolic by-products that 
accumulate during muscle contraction.  This mechanism is at least partly O2 dependent[260]. 
Thus, it is reasonable to propose that early fatigue may underlie exercise intolerance in the 
severe hypoxaemia found in Eisenmenger syndrome.   
 
Thus, against this background, the aims of this part of the study were to investigate whether 
abnormal production of O2 dependent substances contribute to the fatigue and exercise 
intolerance seen in patients with Eisenmenger syndrome. 
 
4.2 Methods 
4.2.1 MRS 
10 adults with Eisenmenger syndrome and 10 age matched controls were studied.  The subject 
was positioned supine and legs first in the MRI scanner (Phillips Achieva 3T scanner). A 
linearly polarised transmitter and receiver 31P coil with a diameter of 14cm was secured over 
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the posterior aspect of the left calf and the left leg was placed in the midline with the centre of 
the coil at the isocentre of the magnet.  
 
Survey images were obtained to check the position of the coil and ISIS (image-selected in 
vivo spectroscopy) technique was used to select a voxel of interest (VOI).  The VOI was 
moved to include the maximum amount of muscle and minimum bone. 2D shimming on the 
tissue water proton signal was used to optimise the magnetic field homogeneity. Manual fine 
adjustment of the centre frequency (F0) was performed if the automatic F0 determination was 
not correct. 
 
Spectra were obtained with a repetition time of 3 seconds with two averages per spectrum.  
Thus the acquisition time for each spectrum was 6 seconds. 
 
4.2.1.1 MRS Exercise 
After one minute of resting data subjects performed plantar flexion of their left foot against a 
resistance pump. Contribution from the quadriceps during the exercise was minimised by 
securing the upper leg to the table. An investigator present in the scan room encouraged 
subjects to maintain a constant pace (approximately 30 extensions per minute) and to work to 
volitional fatigue, that is they felt unable to exercise further. On fatigue they were asked to 
stop, refrain from moving the leg further and recovery data was collected for 5 minutes. 
 
4.2.1.2 MRS Data Analysis 
The spectra were analysed using a time domain fitting programme (AMARES) on jMRUI 
(java-based Magnetic resonance User Interface). Post-processing was performed with Fourier 
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transformation and 5Hz Gaussian line broadening. The PCr peak was used for phase 
correction and quantification was carried out using AMARES[261]. A prior knowledge file 
was used to pre-select the peaks[262]. 
 
The relative concentrations of PCr and Pi were then calculated from the area under the peaks 
for each spectrum throughout rest, exercise and recovery and were plotted against time (figure 
4.1). PCr recovery, expressed as the PCr recovery halftime (t½) was calculated, by graphical 
interpolation, as the time taken to reach 50% of the initial PCr concentration after cessation of 
exercise. Intracellular pH was calculated as previously described in section 4.1.3 and peak 
drop in pH during exercise was calculated. 
 
4.2.2 NIRS 
NIRS was used to measure skeletal muscle oxygenated Hb concentration ([oxy-Hb]), 
deoxygenated Hb (deoxy-Hb]) and total Hb ([HbT]). The probe, an OxiplexTS Near Infrared 
tissue oximeter (ISS Inc., Champaign, IL, USA), is a frequency domain multi-distance NIRS. 
It consists of four light sources and one detector. The light sources are emitted at two separate 
wavelengths, 692nm and 834nm. The NIRS probe limits contribution by skin and 
subcutaneous tissue by using a source-detector distance of 3-4.4cm.  The degree of absorption 
of the light source represents both the concentration of Hb within the microvasculature and 
also the myoglobin in the myocytes.  It is not possible to distinguish between Hb and 
myoglobin due to their identical spectral characteristics. NIRS therefore uses the differences 
in the absorption of the light between oxy-Hb and deoxy-Hb.  Similar absorption of both oxy- 
and deoxy-Hb is seen at a wavelength of 834mm thus absorption is proportional to the [HbT].   
However, at the shorter wavelength of 692nm, the absorption is predominantly by deoxy-Hb 
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and thus differences in absorption at this wavelength reflect changes in [deoxy-Hb]. [Oxy-Hb] 
can thus be calculated by the difference between [HbT] and [deoxy-Hb]. Furthermore, 
alterations of the blood volume within the tissues can be used to reflect changes in the 
[HbT][256]. 
 
The subject was positioned in a comfortable semi-supine position. The dominant arm was 
supported at heart level so that circulation was completely unrestricted and the NIRS probe 
was secured over the flexor digitorum superficialis muscle. A manual pneumatic cuff was 
applied around the upper arm, proximal to the probe.  
 
Continuous measurements of [oxy-Hb], [deoxy-Hb] and [HbT] were recorded for 3 minutes 
of rest. The cuff was then inflated to 200 mmHg for two minutes to induce forearm arterial 
occlusion. Continuous recordings were made throughout this period and for a further two 
minutes after release of the cuff.   
 
During arterial occlusion, the fall of [oxy-Hb] – [deoxy-Hb] was used to calculate the O2 
consumption rate, VO2, of resting muscle. The O2 consumption rate was expressed per 100g 
of muscle as previously described[263]. The ratio of [oxy-Hb] and [HbT] was used to 
calculate muscle O2 saturations.  
 
4.2.3 Fatigue 
Five patients with Eisenmenger syndrome and five healthy volunteers took part in this study. 
This was carried out on a separate day to other forms of exercise testing. The subject was 
positioned in a semi-supine position with their dominant arm extended and supported and the 
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wrist. The hand rested on a handgrip dynamometer. A venous cannula was inserted into this 
arm in the anterior cubital fossa and rest samples for [K+], [Pi], [lactate] and [H+] were taken.  
 
After a rest period of five minutes, the subject was asked to perform a handgrip as hard as 
they could and to sustain this at maximal voluntary effort (MVE) for as long as they were able 
to. Peak force and duration of handgrip were recorded. On release of the handgrip the timer 
was started and bloods were taken immediately for [K+], [Pi], [lactate] and [H+]. Further 
bloods were taken at 3 minutes and 6 minutes.  After seven minutes they were asked to repeat 
the handgrip at MVE, again for as long as they were able to.  On release, bloods were 
repeated at identical time points to before.  
 
Bloods taken during the experiment were placed on ice in an insulated container. The samples 
for [K+], [lactate] and [H+] were analysed using a pHox Plus L analyser (Nova Biomedical, 
Deeside, UK) within 20 minutes of completing the experiment. A separate sample was spun 
down in a centrifuge and the serum was snap frozen using liquid nitrogen.  These samples 
were stored in a -70°C freezer for later analysis of Pi. Unfortunately these samples were lost 
and so never analysed.  
 
4.2.4 Statistical analysis 
Continuous data are expressed as mean ± SEM.  Groups were compared using independent-
samples t-test. The relationship between two variables was assessed by Pearson correlation 
coefficient. A p value of <0.05 was taken as being statistically significant. 
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4.3 Results 
4.3.1 MRS Baseline Data  
Ten subjects with Eisenmenger syndrome and eight healthy control subjects underwent 31P 
MRS of their skeletal muscle. There was no significant difference between the groups in age, 
sex or body mass index (Table 4.1).  Patients with Eisenmenger syndrome had a higher ability 
index score compared to healthy controls and higher haemoglobin due to lower arterial O2 
saturations. The calculated O2 content was higher in the Eisenmenger group than the controls 
(22.3± 0.8 mlO2/100ml vs 19.4±0.5 mlO2/100ml, P<0.05). 
 
4.3.2 Exercise Data 
Figure 4.1 shows a typical example of a spectrum at baseline and at end exercise in a healthy 
control subject. All subjects were able to exercise as instructed until fatigue. Fatigue occurred 
at a similar level of PCr depletion (figure 4.2) in both healthy volunteers (55.6 ± 5.2%) and 
patients with Eisenmenger syndrome (57.3 ± 6.6%, p = 0.8) and there was a similar increase 
in Pi (252.1 ± 16.5% vs 237.6 ± 17.6%, p = 0.5) (figure 4.3), suggesting that patients with 
Eisenmenger syndrome did not stop early.  There was no difference in exercise times between 
healthy controls (218 ± 24s) and Eisenmenger patients (208 ± 12s, p = 0.7) however the 
exercise protocol was not standardised for effort.  
 
4.3.3 pH 
Resting intracellular pH was higher in patients with Eisenmenger syndrome (7.05 ± 0.02) than 
in healthy controls (7.0 ± 0.02) although this did not quite meet statistical significance, 
p=0.08.  Whilst there was a positive correlation between resting intracellular pH and 
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haemoglobin concentration in control subjects (r = 0.374, p = 0.03, figure 4.4a), this was not 
seen in patients with Eisenmenger syndrome (r = 0.29, p = 0.5, figure 4.4b). 
 
The decrease in intracellular pH from baseline during exercise (figure 4.5) was not different 
between the two groups (0.3 ± 0.06 vs 0.28 ± 0.04, p = 0.7).  
 
4.3.4 Recovery Data 
All subjects had recovered their PCr to the baseline value after the five minutes of rest 
following exercise.  There was no significant difference in the PCr recovery t1/2 between the 
healthy controls (34.9 ± 2.9s) and patients with Eisenmenger syndrome (35.2 ± 1.7s, p = 0.9) 
(Figure 4.6). There was a weak negative correlation between age of subject and PCr recovery 
t1/2 within the patient group but this did not reach significance (r = -0.42, p = 0.08). 
 
4.3.5 NIRS Results 
NIRS assessment of muscle O2 consumption was made in five subjects with Eisenmenger 
syndrome and five healthy controls.  There was no difference in age between groups (44 ± 3.8 
vs 42 ± 4.3, p = 0.7).  The patients with Eisenmenger syndrome however had a significantly 
higher haemoglobin (20.1 ± 0.6g/dl) compared to healthy controls (13.5 ± 0.9g/dl, p = 0.001) 
calculated from a venous blood sample.   
 
Figure 4.7 shows typical graphs obtained from NIRS recording. Resting muscle O2 saturations 
were non-significantly higher in the controls (72 ± 4.6%) than the Eisenmenger patients (64 ± 
6.3%, p = 0.3).  Concentrations of oxy-Hb, deoxy-Hb and HbT were all higher in the 
Eisenmenger group than the healthy controls although this did not reach statistical 
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significance, possibly due to the small group size (table 3.2).  On the basis of changes seen 
following arterial occlusion, there was a trend towards higher resting O2 consumption in the 
subjects with Eisenmenger syndrome (0.23 ± 0.06) compared to healthy controls (0.15 ± 0.04, 
p = 0.3) but again this did not reach significance. 
 
4.3.6 Fatigue Results 
Five patients with Eisenmenger syndrome and five healthy control subjects took part in this 
study.  There was no difference in the ages of the two groups (44.0 ± 3.0 vs 39.4 ± 3.0, p = 
0.37). 
 
The patients with Eisenmenger syndrome were able to generate similar peak forces to the 
healthy controls during both handgrips (handgrip 1 20.0 ±1.2N vs 23.9 ± 3.7N, p = 0.37, 
handgrip 2 18.0 ± 1.5N vs 22.0 ± 2.7N, p = 0.27).  The control subjects however were able to 
sustain the MVE for significantly longer than the patients (handgrip 1: 163.0 ± 35.7s vs 89.0 ± 
16.8s, p < 0.05, handgrip 2: 170.0 ± 35.6s vs 77.6 ± 8.5s, p <0.05) indicating early fatigue of 
Eisenmenger patients. 
 
The [H+], expressed as pH, was the same for both groups at rest and at each time point with 
no difference in the fall in pH immediately after each handgrip (figure 4.8a). Patients with 
Eisenmenger syndrome had a trend towards higher [K+] at all time points (figure 4.8b) but 
these values did not reach statistical significance, possibly due to the small sample size.  The 
increase in [K+] after both handgrips was again non-significantly higher in the patients 
compared to the controls (figure 4.8b). The resting [lactate] was significantly higher in 
patients with Eisenmenger syndrome compared to healthy controls. There was a trend for a 
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higher lactate in the patient group at other time points but this did not reach significance 
(figure 4.8c). The increase in lactate after handgrip was similar for both groups. 
 
4.4 Discussion 
This is the first study to specifically investigate the skeletal muscle adaptations in patients 
with Eisenmenger syndrome.  It is known that skeletal muscle mitochondria require a constant 
supply of fuels and O2 to generate energy in the form of ATP. Thus, if hypoxia occurs, such 
as in Eisenmenger syndrome, it seems probable that adaptations must occur to maintain 
cellular energy haemostasis.   
 
The findings of the present study actually showed by using 31P MRS, that patients with 
Eisenmenger syndrome showed a similar fall in PCr at fatigue as controls. Moreover, 
mitochondrial oxidative capacity, as measured by the PCr recovery, was the same in our 
patients with Eisenmenger syndrome as in the group of age matched healthy controls. These 
results differ from previous studies on other groups of patients with cyanotic congenital heart 
disease[254;255] which both showed significantly prolonged PCr recovery in the cyanotic 
patients.  Both of these studies also showed a bigger PCr depletion at peak exercise and larger 
falls in pH during exercise compared to the non-cyanotic controls, which again is in contrast 
with the present findings on Eisenmenger patients. One possible reason for the differences 
may be that the other studies investigated much younger patients than we did.  Miall-Allen et 
al looked only at children[254] and Adatia et al, whilst including some adults, states a mean 
age of 17.3 years[255]. This contrasts to the mean age of 42.6 ± 2.1years for our Eisenmenger 
patients who underwent MRS.  Thus, it could be that the beneficial adaptations to the chronic 
hypoxaemia continue to develop with increasing age; certainly, we showed a weak negative 
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correlation with PCr recovery and age. A further explanation may lie in the heterogeneous 
group of conditions studies in the two earlier studies. They studied a number of conditions 
including those with single ventricle physiology and other factors, including an inability to 
increase cardiac output during exercise, which may account for the abnormally low oxidative 
capacity they reported.  
 
In healthy individuals, mitochondrial oxidative capacity is in part dependent on O2 delivery. 
In response to hypoxia there is an increase in O2 delivery to the tissues by increasing 
ventilation, cardiac output and then an increase in haemoglobin and capillarity[135;264]. In 
the longer term there is also a decreased O2 utilisation, for example by improved substrate 
utilisation. Whilst chronic hypoxia in natives at high altitude is associated with a decreased 
mitochondrial density within the skeletal muscle[156;169], in lowlanders who are 
acclimatised to high altitude ATP production during exercise is maintained by improved 
metabolic efficiency. Thus, more ATP is synthesised per molecule of O2 consumed[187]. This 
may be achieved by the preferential use of carbohydrates during exercise as has also been 
demonstrated in high altitude dwellers[265]. Indeed, a recent study investigating climbers at 
extreme altitude showed preserved skeletal muscle function with no changes in exercising 
metabolites and PCr recovery despite significant muscle atrophy[266]. 
 
Considering patients with Eisenmenger syndrome, they certainly have a significantly higher 
Hb concentration compared to controls. Similarly, the Caudwell Xtreme group of high 
altitude mountaineers also demonstrated a very elevated Hb concentration which maintained 
O2 content or above sea levels up to an altitude of 7100m[267]. In the present study we have 
also shown that Eisenmenger patients have a higher calculated arterial O2 content. This might 
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be expected to aid the local delivery of O2 to the cells even at rest and it might be anticipated 
that delivery may also be enhanced during exercise by augmented local vasodilatation.  
 
In fact, at rest, we demonstrated that the patients with Eisenmenger syndrome had a trend for 
higher O2 delivery, as measured by HbT, and O2 consumption than healthy controls, despite 
there being lower O2 saturations within the muscle.  This is consistent with the idea of 
improved O2 delivery to the muscle in the face of marked hypoxaemia and at least part of this 
will be due to the markedly elevated Hb concentration and O2 content of the blood.  An 
unchanged O2 consumption in skeletal muscle would be consistent with our results from the 
CPET study, which demonstrated a similar whole body VO2 in both Eisenmenger patients and 
healthy controls (see chapter 2).  
 
During exercise we showed, in both the 31P MRS study and by assaying venous blood in the 
fatigue study, that patients with Eisenmenger syndrome have a similar fall in intracellular and 
extracellular pH to the healthy control group.  The pH decrease during exercise is due in part 
to the production of lactate. In acute hypoxia, for example in unacclimatised individuals at 
high altitude, there is a much greater increase in lactate for a given exercise task due to an 
increase in anaerobic metabolism[188].  However, in individuals who are acclimatised to 
hypoxia there are depressed levels of blood lactate[59] and this has been termed the lactate 
paradox. Hochachka describes the functional advantages of this as faster recovery from 
exercise and maintenance of the more energy efficient aerobic metabolism during 
hypoxia[268]. Allen et al also showed that Sherpas, who are phylogenetically adapted to 
hypoxia, have a stable intracellular pH during exercise on 31P MRS[269]. Thus, it appears that 
ATP production becomes more efficient in the hypoxic state. The similar fall in pH on 
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exercise in patients with Eisenmenger syndrome compared to the control group may indicate a 
decreased reliance on anaerobic metabolism.  This would be consistent with our finding from 
the CPET study (chapter 2), which showed that they reach their anaerobic threshold at a 
proportionally later stage of exercise compared to controls.  On the other hand, if you consider 
that the interstitial H+ increases during exercise when ATP usage exceeds oxidative 
phosphorylation[90], the fact that H+ was not raised in Eisenmenger patients may be evidence 
that the efficiency of oxidative phosphorylation is increased. 
 
Whilst our patients with Eisenmenger syndrome were able to generate similar peak forces 
using a handgrip dynamometer, we demonstrated that they fatigue more quickly compared to 
healthy controls. The venous blood samples indicated that K+ and pH, which have been 
considered to be associated with fatigue[78], failed to show any significant differences 
between the patient group and controls.  However, there was a clear trend for higher [K+] at 
all time points in the Eisenmenger patients and this may have become significant if we had 
studied a greater number of subjects.  Thus, it still may be that K+ does contribute to fatigue in 
Eisenmenger syndrome. It is unfortunate that the phosphate samples were lost prior to 
analysis and this gives a further reason to expand this part of the study in the future. 
 
Amann et al investigated the effects of hypoxia severity, from normoxia to severe hypoxia, on 
both the peripheral and central determinants of exercise fatigue in healthy subjects[270]. They 
demonstrated that with increasing hypoxia they switch from a principally peripheral origin of 
fatigue in normoxia, to a more centrally driven origin with increasing levels of hypoxia. Thus, 
patients with Eisenmenger syndrome may also have a significant central drive for their fatigue 
which to date has not been investigated. 
 83
 
Muscle biopsies from patients with Eisenmenger syndrome may also give further information 
regarding the cause for fatigue. For example, in CHF there is a marked increase in fast twitch 
fibres[109-111] which have high concentrations of glycolytic enzymes and fatigue early, 
whereas high altitude natives have increased slow twitch fibres which have greater oxidative 
capacity and are more resistant to fatigue[173].  These have a greater oxidative capacity and 
are more resistance to fatigue.  
 
In summary, from the results described in this chapter, it is clear that the skeletal muscle of 
patients with Eisenmenger syndrome has under gone marked adaptations to become “hypoxia 
tolerant”, with similar mitochondrial oxidative capacities, as measured by PCr recovery and 
similar falls in pH during exercise compared to healthy controls.  Our studies have backed up 
previous work showing that hypoxia-tolerant systems are not reliant on anaerobic metabolism 
despite severe hypoxaemia. The following two chapters investigate whether there are further 
adaptations in the cardiac muscle.
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Figure 4.1 Comparison of skeletal muscle 31P spectra from a healthy control subject at 
rest and at end exercise. It is clear that PCr concentrations fall with a concomitant increase 
in Pi concentration. 
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Figure 4.2 Percentage change in relative PCr concentrations at end exercise 
compared to rest for healthy controls and patients with Eisenmenger syndrome. 
Columns show mean±SEM; (ns = non significant). 
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Figure 4.3 Percentage change in relative Pi concentrations at end exercise compared to 
rest for healthy controls and patients with Eisenmenger syndrome. Columns show mean±SEM; 
(ns = non significant). 
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Figure 4.4 Scatter plot showing relationship between haemoglobin concentration (x-
axis) and resting intracellular pH (y-axis) in control subjects (4.4a) and Eisenmenger 
patients (4.4b) 
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Figure 4.5 Decrease in intracellular pH from baseline resting value at end of 
exercise for healthy controls and patients with Eisenmenger syndrome. Columns 
show mean±SEM; (ns = non significant). 
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Figure 4.6 PCr recovery half-times for healthy controls and patients with 
Eisenmenger syndrome. Columns show mean±SEM; (ns = non significant). 
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Figure 4.7 Typical graphs from NIRS during arterial occlusion in a healthy control subject showing a) 
muscle O2 saturations b) [Oxy0Hb] c) [Deoxy-Hb] d) O2 consumption.  
Dotted line represents start of arterial occlusion; dashed line represents cessation of arterial 
occlusion. 
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Figure 4.8 Effect of static handgrip at 100% MVE on venous efflux of a) pH    b) K+ concentration  c) Lactate. 
Columns represent mean±SEM. In each case, values are shown at rest and at 1, 3 and 6 min after contraction 1 
and contraction 2 as indicated below.  
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Healthy control 
subjects 
(n = 8) 
 
Eisenmenger 
syndrome patients 
(n = 10) 
No of women, (% of n) 
 
6 (75) 6 (60) 
Age (y) 
 
42.6 ± 2.1 41.9 ± 2.3 
Ability index 
 
1.0 ± 0 1.7 ± 0.2* 
Haemoglobin (g/dl) 
 
14.3 ± 0.4 20.4 ± 0.4† 
Baseline O2 saturations (%) 
 
98.3 ± 0.3 79.7 ± 2.1† 
Calculated O2 content  
(mlO2/100ml) 
 
19.4 ± 0.5 22.3 ± 0.8* 
Body mass index (kg/m2) 
 
25.8 ± 1.3 23.1 ± 0.6 
Pulmonary vasodilator 
therapy, n (% of n) 
 
0 (0) 3 (33) 
 
Data are expressed as mean ± SEM.  *P<0.05; †P<0.001 vs control 
 
 
 
Table 4.1 Baseline characteristics of patients undertaking skeletal 
muscle 31P MRS study 
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 Healthy control 
subjects (n = 5) 
Eisenmenger 
syndrome 
patients (n = 
5) 
p value 
Muscle O2 saturations 
(%) 
72 ± 4.6 64 ± 6.3 0.30 
[Oxy-Hb] (µmol) 54.6 ± 4.2 71.8 ± 8.3 0.10 
[Deoxy-Hb] (µmol) 23.3 ±6.0 40.8 ± 9.5 0.16 
[HbT] (µmol) 78.0 ± 10.1 103.1 ± 10.3  0.12 
 
 
Table 4.2 Resting NIRS measurements in Eisenmenger syndrome 
patients and healthy controls 
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5. INVESTIGATION OF RIGHT AND LEFT VENTRICULAR 
FUNCTION WITH ECHOCARDIOGRAPHY 
 
5.1 Introduction 
As discussed in the introduction, patients with Eisenmenger syndrome have preserved right 
ventricular function and clinical heart failure is uncommon. That the RV function remains 
preserved indicates that it must have adapted to maintain contractility in the face of 
pulmonary hypertension. This present study uses echocardiography to investigate the systolic 
and diastolic function of both the right and left ventricles and the role of the interventricular 
septum.  The discussion below provides the background to this study. 
 
5.1.1 Echocardiography and the RV 
Transthoracic echocardiography is the most commonly employed method for the assessment 
of the RV in the routine clinical setting. However, echocardiographic assessment of the RV is 
difficult due to its complex geometry, poor endocardial definition and the load dependency of 
most conventional echo parameters[35]. The American Society of Echocardiography 
recommend that echocardiographic assessment of the RV should use “multiple acoustic 
windows” and the assessment should be based on qualitative and quantitative 
parameters[271]. The parameters they advise are outlined in table 5.1 along with reference 
limits for abnormal results.  
 
5.1.2 Indices of RV Function 
The various indices that can be followed are considered below. 
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FAC  The percentage fractional area change (FAC) is defined as (end-diastolic area – 
end-systolic area)/end-diastolic area x 100.  It is better correlated to RV ejection fraction 
derived from cardiac MRI than other 2D derived indices[272]. Nass et al demonstrated that, in 
patients with a large pulmonary embolism, it can be used as an independent predictor of a 
poor clinical outcome[273]. However, poor endocardial definition can limit its accuracy and 
reproducibility. 
 
TAPSE  Tricuspid annular plane systolic excursion (TAPSE) is a simple and 
reproducible measure of RV function. Although it predominantly assesses longitudinal 
function, it does have a reasonable correlation with radionuclide derived RVEF[274]. TAPSE 
does not assess the septal contribution to RV function and ignores the outlet portion of the 
RV[275;276]. It is also load dependent and thus its accuracy in the presence of severe TR is 
unclear[35].  
 
TDi  Tissue Doppler imaging (TDi) of the RV free wall at the lateral tricuspid 
annulus is a simple, reproducible and quantitative method of assessing RV function. The peak 
systolic excursion velocity (Sm) has good correlation with radionuclide angiography and is 
good at discriminating between normal and abnormal RV function[271]. 
 
MPI  The myocardial performance index (MPI) is a global assessment of RV 
function, incorporating both systolic and diastolic function. It is independent of geometric 
assumptions and is relatively independent of heart rate and loading conditions[35]. It has been 
shown to be a useful predictor of adverse outcome in IPAH[277] and has demonstrated to be 
accurate in congenital heart disease; Eidems et al showing a higher MPI with increasing RV 
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dysfunction in patients with Ebstein’s anomaly, a condition characterised by a complex RV 
anatomy[278;279].  
 
IVRT  Isovolumic relaxation time (IVRT) is the period of the cardiac cycle after the 
aortic valve closes and before the mitral valve opens. During this period tension of the 
myocardial fibres reduces without any lengthening thus the volume remains unaltered. In 
diastolic dysfunction there is a deterioration in active relaxation with a prolonged IVRT[280]. 
It has been demonstrated to be prolonged in patients with PAH and improves with a reduction 
in the RV afterload[281]. 
 
IVA  Isovolumic acceleration (IVA) is a TDi-derived parameter that reliably 
assesses the intrinsic contractility of the RV[282]. It has been shown to be less load dependent 
than other indices under a range of physiological conditions[282;283] and correlates with the 
severity of disease in both repaired tetralogy of Fallot[284] and in patients with an atrial 
switch for transposition of the great arteries whose RV is characterised by pressure 
overload[285]. 
 
5.1.3 Echocardiographic Assessment in Eisenmenger Syndrome 
The majority of studies using echocardiography to assess RV function in Eisenmenger 
syndrome describe the RV function in mostly qualitative terms. For example Daliento et al 
describe a visual assessment of global RV function[16].  This limits our understanding of the 
pathophysiological process leading to any RV dysfunction. 
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Kalogeropoulos et al used both M-mode and Doppler derived indices, including RV strain, to 
compare RV function in patients with Eisenmenger syndrome, PAH not due to congenital 
heart disease and subjects with a structurally normal hearts[36].  They demonstrated a 
preserved short axis function in patients with Eisenmenger syndrome compared to PAH but 
longitudinal function was depressed in both groups.  They comment that conventional 
assessment of RV function which is heavily dependent on longitudinal function may not be 
suitable for patients with Eisenmenger syndrome.  
 
On the other hand, Moceri et al carried out a longitudinal echocardiographic study of 
Eisenmenger syndrome patients over a six year period[286]. They report that most patients 
have maintained or only mildly impaired RV function as described by TAPSE or TDi derived 
systolic velocities. They also found that a decreased TAPSE is a predictor of poor outcome. 
Similarly, Van de Bruaene et al demonstrate that patients with a TAPSE of <16mm have  a 
lower event-free survival and a greater all-cause mortality[287]. TAPSE has also been shown 
to be strongly related to survival in IPAH although the authors do comment that TAPSE may 
be overestimated in the presence of significant TR[288]. 
 
To date no studies have examined the contribution of septal function or diastolic dysfunction 
to the known exercise intolerance and dyspnoea in Eisenmenger syndrome. We also examined 
the left ventricular systolic and diastolic function and looked for correlation between RV and 
LV function in the presence of a large intracardiac shunt.  
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5.2 Methods 
5.2.1 Data Acquisition 
10 patients with Eisenmenger syndrome and 9 age matched healthy controls were studies.  All 
subjects were scanned using a Vivid 7 cardiac ultrasound system and a standard adult 2D 
probe (GE Healthcare). Data was analysed off line using a dedicated workstation and 
EchoPAC software (version 108.1.4, GE Healthcare). Patients were positioned in a left 
decubitus position with their left arm raised to spread the ribs and optimise their acoustic 
window.  Images were normally obtained during quiet respiration. If images were obtained in 
held expiration then valsalva was avoided. ECG gating was used in all subjects. 
 
The frame rate was optimised to a minimum of 40 frames per second by reducing the depth 
and sector width as appropriate. The image was focused on the structure of interest.  The loop 
length was set at five beats.  Ectopic beats and beats post ectopics were avoided. 
Measurements were made on three consecutive beats and the final value was the mean of 
these. 
 
Chamber quantification of the left and right ventricles, doppler quantification and tissue 
Doppler imaging were performed as described by the American Society of 
Echocardiography[271;289;290].  
 
5.2.2 Assessment of Left Ventricle 
Dimensions  Left ventricular dimensions were measured using M Mode in the 
parasternal long axis view (PLAX).  The cursor was positioned through the tip of the mitral 
valve leaflets. Septal and posterior wall thickness and LV cavity diameter were obtained at 
 99
end diastole and end systole. If it was not possible to position the cursor perpendicular to the 
long axis, measurements from 2D were performed. 
 
Ejection fraction The left ventricular ejection fraction (LVEF) was calculated using the 
modified Simpson’s biplane method as previously described[291].  In brief, the LV end 
diastolic volume (EDV) and end systolic volume (ESV) were calculated from the summation 
of a stack of elliptical discs. The endocardial borders were manually traced, avoiding the 
papillary muscles, in both the apical four chamber (A4C) and apical two chamber (A2C) 
views. End diastole was taken as either the onset of the QRS or one frame after mitral valve 
closure.  End systole was taken as the frame preceding mitral valve opening.  In the A2C the 
mitral valve was not always clearly visualised and the frames at which the ventricle appeared 
the biggest or smallest were used. The ventricle is then divided along its long axis into a series 
of discs of equal height. The stroke volume (SV) is calculated as EDV – ESV. The ejection 
fraction is then calculated as SV/EDV.  
 
Mitral inflow  Pulsed wave (PW) Doppler was used with the sample volume at the 
tips of the mitral valve leaflets in the A4C view. Peak forward velocities (E wave and A 
wave) and deceleration time of the A wave were recorded, 
 
Isovolumic relaxation time  Continuous wave (CW) Doppler cursor was positioned in an 
intermediate position between the inflow and outflow signals in the apical five chamber view. 
The IVRT was calculated as the interval from the closure of the aortic valve to the opening of 
the mitral valve.  
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Stroke volume  LV stroke volume (SV) was calculated as the product of the left 
ventricular out flow tract (LVOT) cross sectional area and LVOT velocity.  The LVOT area 
was derived from the diameter in the PLAX view, making the assumption that it is circular in 
systole (area = πr2).  LVOT velocity was measured using PW Doppler in the apical five 
chamber view with the sample volume 5mm proximal to the aortic valve. The SV was 
indexed for body surface area. 
 
Tissue Doppler imaging A high frame rate was obtained (>100 frame/sec) by reducing 
the depth and sector width. The A4C view was used but the views were modified to keep the 
angle of alignment to <15° from the motion direction to minimise error.  TDi velocities were 
obtained for the lateral wall and septum by placing a 3-5mm pulsed Doppler sample volume 
at the junction of the LV wall with the mitral annulus of the lateral and septal myocardial 
segments. Peak velocities during systole (Sm), early diastole (E’) and late diastole (A) were 
measured.  
 
Myocardial performance index LV MPI was calculated using values derived from PW 
Doppler.  The LV ejection time, IVRT and IVCT were all measured and the MPI was 
calculated using the following equation: 
MPI = (IVCT + IVRT) 
                       ET 
 
5.2.3 Assessment of Right Ventricle 
Dimensions   The basal RV end diastolic diameter was measured using 2D in 
a RV focused A4C view.    
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Fractional area change The RV endocardial border was traced in the A4C view from 
the tricuspid annulus, along the free wall to the apex, and back to the annulus along the 
septum at end systole and end diastole. Trabeculations were traced under. 
 
The FAC was then calculated as: 
  FAC = (end-diastolic area – end-systolic area)   x   100 
    end-diastolic area 
 
Tricuspid inflow  Pulsed wave (PW) Doppler was used with the sample volume at 
the tips of the tricuspid valve leaflets in the A4C view. Peak forward velocities were recorded. 
The IVRT and IVCT were calculated from the TV inflow. 
 
TAPSE    The TAPSE was acquired by  placing the M mode cursor 
through the lateral aspect of the tricuspid valve annulus in the A4C view. The longitudinal 
distance moved by the annulus during systole is then measured. 
 
Tissue Doppler Imaging The image was optimised as for the LV. A 3-5mm pulsed 
Doppler sample volume was placed approximately 1cm towards the RV apex from the lateral 
TV annulus in the A4C view, ensuring the alignment was <15° to the RV free wall. Peak 
systolic velocity (Sm) was measured. The isovolumic acceleration time was measured as the 
time to peak velocity in systole at the lateral TV annulus. 
 
Myocardial performance index (MPI) The RV MPI was assessed using the PW 
Doppler method as for the LV. 
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5.2.4 Statistical Analysis 
Continuous data are expressed as mean ± SEM.  The data was normally distributed and thus 
groups were compared using independent-samples t-test. The relationship between two 
variables was assessed by Pearson correlation coefficient. A p<0.05 was taken as being 
statistically significant.  
 
5.3 Results 
5.3.1 Baseline Data 
Ten subjects (six female) with Eisenmenger syndrome aged 31 – 50 years (mean 43 ± 1.9 
years) underwent echocardiography.  Seven had an underlying isolated VSD, one had a VSD 
and a PDA, one had an ASD and one had an AVSD.  Three patients were on selective 
pulmonary vasodilators (two bosentan, one sildenafil). Their mean Hb was 20.5 ± 0.4g/dl with 
resting O2 saturations of 80.6 ± 1.9%. 
 
Nine healthy age matched controls (seven female) aged 33-53 years (mean 42 ± 2.2 years) 
also underwent echocardiography.  All were free from cardiovascular, pulmonary and other 
systemic disease. Their mean Hb was significantly lower (14.2 ± 0.4g/dl, p < 0.001) and their 
resting O2 saturation higher (98.3 ± 0.2%, p < 0.001). 
 
5.3.2 Left Ventricular Indices 
The left ventricular size, as measured by the left ventricular end diastolic diameter (LVEDD), 
was normal in both patients with Eisenmenger syndrome (4.1 ± 0.15cm) and healthy controls 
(4.4 ± 0.2cm, p = 0.2).  The global systolic function was also normal with no difference 
between the Eisenmenger group and control group (LVEF 57 ± 4.1% vs 65 ± 2.4%, p = 0.12). 
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There was a trend towards a higher indexed stroke volume in the Eisenmenger group 
(42.7ml/m2 vs 33.2ml/m2, p = 0.07) reflecting the large intracardiac shunt. The longitudinal 
function, assessed by the systolic motion of the lateral MV annulus towards the apex (Sm), 
was similar and within the normal range for the Eisenmenger group (9.5 ± 1.2cm/s) and 
control group (10.5 ± 1.1cm/s, p = 0.5). The longitudinal function of the septum however, 
measured by the Sm of the septum, was significantly reduced in the Eisenmenger group (6.0 ± 
0.9cm/s vs 9.6 ± 0.6cm/s, p = 0.006).  
 
Left ventricular diastolic function also appeared to be similar between the Eisenmenger group 
and control group (table 5.2) with no significant difference in MV E/A ratio, peak E velocity, 
deceleration time or IVRT.  The E/E’ ratio, which correlates with the pulmonary capillary 
wedge pressure and thus left atrial pressure, was also similar in subjects with Eisenmenger 
syndrome and healthy controls (8.1 ± 2.1 vs 5.7 ± 0.8, p = 0.34). 
 
The MPI was higher in the patients with Eisenmenger syndrome than the healthy controls 
although this did not reach statistical significance (0.48 ± 0.05 vs 0.36 ± 0.03, p = 0.08).  The 
mean value for the Eisenmenger group was higher than the accepted normal range (<0.4) 
suggesting mild ventricular impairment.  The MPI is an index of global function and may 
reflect the abnormal septal motion. 
 
5.3.3 Right Ventricular Indices 
The RV was mildly dilated in patients with Eisenmenger syndrome, as measured by right 
ventricular end diastolic diameter (RVEDD) and was significantly larger than the RV of 
healthy controls (basal RVEDD 4.3 ± 0.2cm vs 3.3 ± 0.14cm, p = 0.015).  
 104
 
The RV systolic indices are shown in table 5.3. The RV fractional area change was lower in 
the Eisenmenger group than the control group although this did not quite meet statistical 
significance. (47.4 ± 4.2% vs 56.8 ± 2.2%, p = 0.08) (figure 5.1). The TAPSE was also 
significantly lower in the Eisenmenger group (17.4 ± 0.7mm vs 24.7 ± 1.0, p < 0.001) (figure 
5.2) However, the values obtained in the patients with Eisenmenger syndrome are still within 
the normal range previously discussed in section 5.1. 
 
The RV longitudinal function, as measured by the TDI of the RV free wall, was lower in the 
Eisenmenger group than the control group (Sm (12.4 ± 0.8cm/s vs 16.2 ± 1.1cm/s, p < 0.001) 
(figure 5.3) but this again does fall below the normal range. 
 
There was no difference in the IVA between the Eisenmenger group and control group (4.3 ± 
0.3 vs 4.4 ± 0.4, p= 0.8) indicating that the intrinsic contractility is not impaired in 
Eisenmenger syndrome.  
 
The RV diastolic indices are shown in table 5.4. The IVRT was prolonged in the patients with 
Eisenmenger syndrome compared to healthy controls (72.6 ± 2.2 vs 62.3 ± 5.3ms, p = 0.05) 
(figure 5.4) suggesting an abnormality of diastolic relaxation.  The E/E’ was also significantly 
higher in the Eisenmenger patients than the control subjects (6.3 ± 1.0 vs 3.3 ± 0.3, p = 0.012) 
(figure 5.5) as was the A’/E’ ratio (2.0 ± 0.5 vs 1.0 ± 0.1, p = 0.04) (figure 5.6). This 
parameter has been shown to correlate with an elevated RV end diastolic pressure[292;293]. 
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The RV MPI was significantly elevated in patients with Eisenmenger syndrome compared to 
healthy controls (0.65 ± 0.04 vs 0.34 ± 0.04, p < 0.001) (figure 5.7). This value suggests that 
the global function of the RV was mildly impaired. However, the RV ejection time was lower 
in the Eisenmenger group compared to controls (252 ± 12ms vs 281 ± 13ms, p = 0.11), 
although this did not meet statistical significance; and this may account for the higher MPI in 
this group.  
 
There was a trend towards a positive correlation between left ventricular and right ventricular 
MPI (figure 5.8) in patients with Eisenmenger syndrome (r = 0.4, p = 0.24) but no correlation 
between these indices was seen in healthy control subjects (r = 0.2, p = 0.63).  
 
5.4 Discussion 
In pulmonary hypertension the survival and disease progression is, at least in part, related to 
the ability of the RV to adapt to the significantly elevated pulmonary artery pressures rather 
than the degree of vascular injury[294]. Accordingly, RV failure has been shown to be 
associated with a poor outcome in Eisenmenger syndrome [16] and is the main cause of death 
in PAH from all causes[47]. 
 
In the present study we showed that right ventricular systolic function in patients with 
Eisenmenger syndrome, as measured by FAC and TAPSE, is preserved and there is normal 
intrinsic contractility. This preservation of function may, in part, help to explain their better 
than expected survival when compared to PAH from other causes. The exact reason for the 
relatively maintained RV function is not known but there are several different possibilities. 
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Ventriculoarterial (VA) coupling is a simultaneous assessment of ventricular performance and 
arterial elastance. It is expressed as the ratio of effective arterial elastance to end systolic 
elastance. Sanz et al used right heart catheterisation and cardiac MRI to look at the RV VA 
coupling in PAH[295]. They demonstrate that in early disease there is preservation of VA 
coupling by an increase in contractility in proportion to the increased afterload. However, 
with disease progression, the RV is unable to increase contractility adequately resulting in VA 
uncoupling and RV failure.  
 
In high right ventricular afterload states, such as in TGA with an atrial switch or cTGA, it has 
been suggested that one way the RV adapts is by alterations in the geometry and myocyte 
fibre architecture[45;46]. Thus, the RV starts to resemble a normal LV and enhances 
ventriculoarterial coupling through preserved contractility. Thus, our results, indicating a 
normal RV contractility with a preserved IVA in patients with Eisenmenger syndrome, may 
may lead to maintained VA coupling and thus preserved RV function.  
 
We did find that the longitudinal RV systolic function, as measured by the systolic velocity of 
the lateral tricuspid valve annulus using TDi, was decreased when compared to our healthy 
controls. An increased systemic arterial stiffness, such as that arising with advancing age or 
hypertension, has been demonstrated to lead to a reduction of the subendocardial fibres of the 
left ventricle resulting in a reduction of longitudinal function[296]. Thus, it is plausible that a 
similar effect occurs in the right heart. In other words, an increased pulmonary arterial 
stiffness, arising from pulmonary vascular remodelling, may lead to a reduction in the RV 
longitudinal function. However, the decrease in longitudinal function observed in our study 
 107
was only mild and may have reflected a shift in the RV free wall from longitudinal to 
circumferential shortening in response to pressure overload[45]. 
 
Tan et al demonstrated that the RV is adapted less well in IPAH patients than in those with 
TGA or cTGA[46]. This is likely to be due to the ability of the RV to adapt when faced with 
high pressures from birth or in the early neonatal period, as opposed to de novo PAH in 
adulthood. In Eisenmenger syndrome, the right ventricle has been exposed to systemic 
pressures from infancy and it is feasible that this time has allowed it to adapt, possibly in a 
similar way to the RV in TGA or cTGA. 
 
Whilst our results show that the RV systolic function is maintained in patients with 
Eisenmenger syndrome, there was evidence of diastolic dysfunction and elevated RV end 
diastolic pressures. Thus the problem appears to be one of abnormal early relaxation of the 
ventricle.  Tan et al reported a similar pattern in patients with IPAH with abnormal early 
diastolic function, as shown by prolonged IVRT with a secondary fall in filling time[46]. 
Diastolic dysfunction has also been demonstrated in chronic hypoxia in healthy individuals 
investigated during expeditions to altitude with decreased early filling[297;298]. This may 
represent a failure to meet the energy requirements of the active relaxation that occurs in early 
diastole.  
 
A further explanation for the RV diastolic dysfunction may be progressive fibrosis of the 
myocardium. Myocardial fibrosis is known to occur in diseases associated with left 
ventricular hypertrophy, such as hypertension and hypertrophic cardiomyopathy, and leads to 
increased stiffness and thus impaired relaxation of the ventricle[299].  Congenital conditions 
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associated with pressure or volume overloaded RVs, including TGA and tetralogy of Fallot, 
have also been demonstrated to have late gadolinium enhancement, suggestive of fibrosis, on 
cardiac MRI[300;301].  Whilst patients with Eisenmenger syndrome have not been previously 
investigated in this way, Blyth et al have demonstrated fibrosis affecting the septum in 
patients with IPAH with the degree of fibrosis correlating well to the RV function[302]. Areas 
of fibrosis in the RV of patients with Eisenmenger syndrome have also been reported in post 
mortem studies[303].  
 
In contrast to the RV, our study has shown normal diastolic function of the LV in patients 
with Eisenmenger syndrome. This differs from PAH from other causes in which diastolic 
dysfunction of the LV, with a delayed pattern of relaxation, is common[35]. Further, Kitahori 
et al used an animal model with pulmonary artery banding to create pressure overload and 
subsequent RVH in infancy[304]. This also resulted in left ventricular diastolic dysfunction 
with preservation of ejection fraction. They describe septal and LV apoptosis, pathological 
remodelling of the LV and a reduction in capillary density.  
 
Even though LV diastolic function appears normal in Eisenmenger syndrome in the resting 
state, it is possible that it becomes impaired during exercise. This has been demonstrated to 
occur in patients with well treated systemic hypertension with normal resting 
echocardiography in whom exercise results in widespread diastolic dysfunction[305]. 
 
It is also possible that systolic dysfunction of both the RV and LV occurs during exercise in 
patients with Eisenmenger syndrome. Tan et al looked at the effects of exercise on patients 
with heart failure with normal ejection fraction (HFNEF) who are characterised by resting 
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diastolic abnormalities[306]. During exercise the authors describe widespread abnormalities 
of both systolic and diastolic function and conclude that it is not an isolated disorder of 
diastole as previously thought. Systolic dysfunction during exercise may contribute towards 
the exercise intolerance in patients with Eisenmenger syndrome and this warrants further 
investigation. 
 
The relative preservation of RV systolic function may also be related to the presence of a 
large right to left shunt. During exercise, patients with Eisenmenger syndrome are unable to 
increase their cardiac output by reducing their PVR. Instead they increase it by increasing the 
size of the shunt, at the expense of increasing cyanosis. Thus the shunt may protect the right 
ventricle from some of the effects of pressure overload. 
 
The use of conventional echocardiographic parameters to assess the RV function in 
Eisenmenger syndrome has been debated, in particular those that measure longitudinal 
function such as TAPSE.  
 
Whilst TAPSE is easily measured and highly reproducible, it ignores the outlet portion of the 
RV and also the septal contribution. In the normal heart it has been validated as the 
longitudinal displacement of the RV base accounts for most of the RV function. However, as 
discussed in section 1.3.1, the septum accounts for a greater proportion of the RV contraction 
in severe PAH suggesting that TAPSE may not accurately reflect the RV function in this 
situation. TAPSE is also volume dependent and may be overestimated in the presence of 
significant tricuspid regurgitation such as is found in PAH. Two recent studies, however, have 
found that a reduced TAPSE is a predictor of poor outcome in Eisenmenger 
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syndrome[286;287]. In the present study the mean TAPSE was lower than that of the healthy 
controls, although still above the normal range given by the ASE[271].  
 
The MPI is a relatively load-independent measure of global ventricular function. Our results 
showed that the RV MPI was higher in the Eisenmenger group than controls. However, this 
may be due to the diastolic dysfunction or the shortened ejection time resulting from reduced 
pulmonary artery compliance[307]. To date there has not been a study looking at the 
association with the MPI and outcome in this patient group. The LV MPI also tended to be 
higher in Eisenmenger patients than in controls, although this did not reach significance. This 
may reflect the dyssynchronous septal motion in severe pulmonary hypertension as the 
septum assumes greater importance for RV contraction. This interaction between the 
ventricles was also demonstrated by the trend towards a positive correlation between the RV 
and LV MPI in patients with Eisenmenger syndrome. 
 
In summary the present results show that the overall RV systolic function in Eisenmenger 
syndrome is maintained at rest, as suggested by previous studies. In addition, the present 
study results are the first to demonstrate diastolic dysfunction of the RV in these patients; may 
be due to myocardial fibrosis as a result of years of high afterload. The reason for the 
maintained systolic function is not clear and newer echocardiographic techniques such as 
strain rate, speckle tracking and exercise echo, may provide further answers. 
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Table 5.1 Recommended measures of RV assessment and their reference limits.  Adapted 
from Rudski et al[271] 
Variable Units Abnormal 
Right ventricular size 
· Basal (A4C) 
· Mid cavity (A4C) 
 
cm 
cm  
 
>4.2 
>3.5 
Right ventricular systolic function by at least 1 of: 
· FAC 
· Tissue doppler velocity at annulus  
· TAPSE 
· MPI  
 
% 
cm/s 
mm 
- 
 
<35 
<14 
<16 
<0.4 
Pulmonary artery systolic pressure mmHg >36 
A4C, apical four chamber; FAC, fractional area change; TAPSE, tricuspid annular plane 
systolic excursion; MPI, myocardial performance index. 
The reference limits for both tissue Doppler velocity and MPI are for pulse spectral technique 
of data acquisition. 
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Table 5.2 Indices of left ventricular diastolic function in Eisenmenger syndrome patients 
and healthy controls. All values are given as mean±SEM, NS; not significant 
 Eisenmenger syndrome 
patients 
Healthy control 
subjects 
p value 
Peak E velocity 
(m/s) 
0.67 ± 0.06 0.71 ± 0.05 NS 
DT (ms) 
 
184 ± 27.9 247 ± 16.7 NS 
E/A ratio 
 
1.23 ± 0.25 
 
1.14 ± 0.1 
 
NS 
 
IVRT (ms) 80 ± 3 76 ± 4 NS 
 
E/E’ 8.1 ± 2.1 5.7 ± 0.8 NS 
DT, deceleration time; IVRT, isovolumic relaxation time 
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Table 5.3 Indices of right ventricular systolic function in Eisenmenger syndrome patients 
and healthy controls. All values are given as mean±SEM, NS; not significant 
 
 Eisenmenger syndrome 
subjects 
Healthy control 
subjects 
p value 
FAC (%) 47.4 ± 4.2  56.81 ± 2.2 NS 
TAPSE (mm) 17.4 ± 0.7 24.7 ± 1.0 0.001 
TDi Sm (cm/s) 
IVA (m/s) 
1.23 ± 0.25 
4.3 ± 0.3 
1.14 ± 0.1 
4.4 ± 0.4 
<0.001 
NS 
FAC, fractional area change; TAPSE, tricuspid annular plane systolic excursion; TDi, tissue 
Doppler imaging; IVA, isovolumic acceleration 
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Figure 5.4 Indices of right ventricular diastolic function in Eisenmenger syndrome 
patients and healthy controls. All values are given as mean±SEM, NS; not significant.  
  
 Eisenmenger syndrome 
subjects 
Healthy control 
subjects 
p value 
IVRT (ms) 72.6 ± 2.2 62.3± 5.3 0.05 
E/E’ 6.3 ± 1.0 3.3 ± 0.3 0.012 
A’/E’ 2.0 ± 0.5 1.0 ± 0.1 0.04 
IVRT, isovolumic relaxation time 
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Figure 5.1 Right ventricular fractional area change in healthy controls 
and patients with Eisenmenger syndrome 
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Figure 5.2 Tricuspid annular plane systolic excursion in healthy controls 
and patients with Eisenmenger syndrome. *** p<0.001 
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Figure 5.3 Right ventricular free wall peak systolic velocity (Sm) in healthy 
controls and patients with Eisenmenger syndrome. ** p<0.01 
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Figure 5.4 Right ventricular isovolumic relaxation time in healthy controls and 
patients with Eisenmenger syndrome. ** p<0.01 
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Figure 5.5 Ratio of peak E wave velocity through tricuspid valve (E) and tissue 
Doppler derived early diastolic velocity (E’) in healthy controls and patients with 
Eisenmenger syndrome. ** p<0.01  
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Figure 5.6 Ratio of right ventricular late diastolic (A’) and early diastolic velocity in 
healthy controls and patients with Eisenmenger syndrome. ** p<0.01 
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Figure 5.7 Right ventricular myocardial performance index in healthy 
controls and patients with Eisenmenger syndrome. *** p<0.001 
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5.8a 5.8b 
Figure 5.8 Relationship between left and right ventricular myocardial performance 
index in control subjects (5.8a) and Eisenmenger patients (5.8b) 
r = 0.2, p = 0.6 r = 0.4, p = 0.24 
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6. COMPARISON OF CARDIAC ENERGETICS IN PATIENTS WITH 
EISENMENGER SYNDROME AND CONTROLS 
 
6.1 Introduction 
As indicated in the introduction, very little is known of cardiac muscle energetics in patients 
with Eisenmenger syndrome.  Thus, in the present studies, 31P MRS was used as means of 
assessing PCr and ATP. The discussion below provides the background to these studies.  
 
6.1.1 Cardiac 31P MRS 
Magnetic resonance spectroscopy (MRS), as discussed in section 4.1, is a non-invasive 
technique that allows the in-vivo assessment of myocardial energetics. 31P MRS measures the 
high energy components of PCr, adenosine triphosphate (ATP), 2,3 Diphosphoglycerate (2,3-
DPG) and phosphodiester (PDE) compounds with the PCr / ATP ratio reflecting the energetic 
state of the myocardium. A typical spectrum obtained from cardiac 31P MRS is shown in 
figure 6.1. 
 
6.1.2 Myocardial Energetics and Metabolism 
The myocardium relies on ATP production for both contractile function and cell viability. It is 
capable of consuming 20-30 times it own weight in ATP per day[308]. Whilst it is able to 
respond to large variations in energy demand and substrate availability, with ATP production 
being loosely coupled to myofibrillar contraction, it has limited capacity for energy 
storage[309]. Thus, the myocardial cell must continually re-synthesise ATP to maintain 
normal myocardial function with even small variations in the efficiency of ATP production or 
utilisation having a significant impact on cellular energy levels[310]. 
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In aerobic conditions, β-oxidation of free fatty acids account for 60-90% of the energy 
generated by ATP re-synthesis with carbohydrate metabolism, in normal circumstances, only 
contributing 10-40%[311]. As discussed previously in section 1.4.2.4, whilst fatty acid 
oxidation has a higher ATP yield per mole compared to glucose, it does so at a higher O2 cost, 
requiring 10-15% more O2 to generate an equivalent amount of ATP when compared to 
glucose[53].  High rates of fatty acid oxidation also suppresses glucose oxidation by directly 
inhibiting pyruvate dehydrogenase thereby increasing lactate concentrations, reducing pH and 
further impairing the myocardial contractile function[312].  
 
Not surprisingly, suppression of fatty acid uptake or oxidation by any means increases 
myocardial glucose substrate utilisation and this has been a recent focus for therapeutic agents 
used in both ischaemic heart disease and chronic heart failure such as perhexiline, 
trimetazidine and ranolazine[53;313].  
 
6.1.3 Abnormal Energetics in Cardiovascular Disease States 
Even small changes in the efficiency of energy production by the myocardium can have a 
significant affect on the cell’s energy levels.  The creatine kinase equilibrium strongly favours 
ATP synthesis over PCr synthesis. Therefore, when the demand for ATP outweighs the 
synthesis of ATP, there is an initial fall in PCr, with a resultant low PCr / ATP ratio[239]. 
Abnormal myocardial energetics, demonstrated by a low PCr / ATP ratio using 31P MRS, 
have been described in several cardiac disease states including left ventricular failure[314], 
valvular heart disease[315] and hypertrophic cardiomyopathy[316]. Modulation of the 
energetics is the focus for several new therapeutic approaches.  
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Considering congenital heart disease, Miall et al investigated at the myocardial energetic 
status of babies and children. They showed that the PCr / ATP ratios were similar in controls 
and those who were hypoxaemic only; however they were significantly lower in those with 
heart failure and hypoxaemia[254]. An impaired high energy phosphate metabolism has also 
been described by Spindler et al in idiopathic pulmonary arterial hypertension[317]. They 
demonstrated a reduced PCr / ATP ratio in a patient with rapidly deteriorating symptoms. 
After administering bosentan, a selective pulmonary vasodilator, for six months the PCr / 
ATP ratio had significantly increased and this was associated with improved functional class 
and six minute walk distance. 
 
To date, there are no studies investigating the myocardial energetic status of adults with 
cyanotic heart disease including Eisenmenger syndrome.  Thus, we have investigated the 
energetics of the septum, focusing on this region because of the increased importance it 
assumes in RV contraction in severe pulmonary hypertension (see section 1.3.1). 
 
6.2 Methods 
6.2.1 Acquisition 
Eight patients with Eisenmenger syndrome and six age matched healthy volunteers (HV) were 
studied. 31P cardiac magnetic resonance spectroscopy was carried out using a Phillips Achieva 3T 
scanner (Philips Healthcare, Best, the Netherlands) as previously described and validated[261]. A 31P 
linearly polarized transmitter and receiver coil with a diameter of 14 cm (figure 6.2) was used to 
acquire the data and was performed using ISIS (image-selected in vivo spectroscopy) volume 
selection[318]. 
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Subjects were positioned in the supine position and the coil was placed on the chest wall, directly 
over the heart, and secured with straps. Once in the magnet, the position of the coil was checked using 
survey images (figure 6.3) and the patient and / or coil were repositioned if necessary so that the 
distance between the coil and the septum was kept to a minimum[319]. Subjects were to be excluded 
if the distance of the coil to the region of interest was greater than 9cm to decrease any potential 
artefacts from chemical shift that are known to be present with a 3T scanner[261]. Minimising this 
distance and decreasing artefacts ensures that the chemical shift displacement of PCr and ATP is 
<10%[261]. In practice, no subjects from either group were excluded. 
 
An image-guided shim volume was used for the shimming and this was positioned to include the 
whole myocardium. The shimming quality was subsequently assessed using a short axis stack and 
from this the trigger delay was also calculated for ECG gating. To ensure that the spectra were 
acquired during diastole, when cardiac movement was minimal, a trigger delay was set by subtracting  
250-300ms from the total cardiac cycle[261].  
 
The 3-D voxel of interest (VOI) was subsequently planned to include as much of the septum and apex 
as possible. The right ventricular cavity was avoided to minimise contamination from blood. In all 
subjects, the voxel size was 89.54 ml (44 x 55 x 37 mm3) thus allowing comparisons between 
subjects[316]. 
 
1H spectra were acquired first from this VOI using a repetition time of 2000ms. This gave a total scan 
time of 16 s. This further ensured shim quality and correct F0 determination. F0 was manually 
adjusted using tuning rods if required. Following this the 31 P spectra were acquired with a repetition 
time of 10000 ms, which has been shown to be optimal to adequately reduce saturation effects whilst 
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keeping the scan time to a minimum. 136 averages were taken with 512 sample giving a total scan 
time for the acquisition of 31P spectra of 23 minutes.  
 
6.2.2 Analysis 
The spectra were analysed using a time-domain fitting programme (AMARES) on jMRUI (java-based 
Magnetic resonance User Interface). Fourier transformation and 15Hz Gaussian line broadening were 
used to perform post-processing[261]. Phase correction was performed with PCr as the reference 
peak. The peaks of 2,3-DPG, PDE, PCr, γ-ATP, α-ATP and β-ATP were identified and their 
concentrations calculated as the area under the peaks.  
 
6.2.2.1 Correction for Blood Contamination 
The PCr/ATP ratio may be artificially reduced if the VOI includes blood, which contains ATP but not 
PCr[240]. Blood also contains 2,3 DPG, observed between 5.4 and 6.3 on the spectra. The degree of 
contamination can thus be calculated by the ratio between ATP and DPG. Conway et al describe one 
method to correct the value of the ATP peak for blood contamination[315]. The size of the γ-ATP 
was reduced by an amount equal to one sixth of the area of the combined peaks representing 2,3 DPG. 
This correction factor was applied if the area from the combined 2,3 DPG resonances were equal or 
greater than the γ-ATP peak or if the amplitude of 3 DPG was less or equal to 2 DPG.  
 
6.2.2.2 Cramer-Rao Lower Bounds 
The quality of the signal to noise ratio (SNR) of the spectra was further assessed using coefficient of 
variation in the measured PCr/ATP value and was based on the Cramer-Rao lower bounds 
(CRLB)[320].  Their calculated coefficient of variation denotes a 95% Student’s –t interval for the 
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measurement of PCr/ATP from the acquired spectrum and a low CRLB indicates the spectra were of 
good quality and with good reproducibility[321]. 
 
6.2.3 Statistical analysis 
Continuous data are expressed as mean ± SEM.  Groups were compared using independent-
samples t-test. The relationship between two variables was assessed by Pearson correlation 
coefficient. A p value of <0.05 was taken as being statistically significant. 
 
6.3 Results 
6.3.1 Baseline Data 
Eight patients with Eisenmenger syndrome (five female) aged 31-50 years,(mean 41.5 ± 2.7 
years), underwent cardiac 31P MRS. Seven of these subjects had an underlying VSD, one with 
a co-existent PDA, and one had an AVSD. One patient was on a selective pulmonary 
vasodilator (bosentan). Their mean Hb was 20.5 ± 0.5g/dl with resting O2 saturations 80 ± 
2.1%. The ability score was I in four patients, II in three patients and III in one.  
 
The control group consisted of six healthy volunteers (four female) aged 30-48 years, (mean 
40.3 ± 3.0 years). All controls were free from cardiovascular and pulmonary disease. Their 
mean Hb was significantly lower than the Eisenmenger group (14.1 ± 0.65g/dl, p<0.001) and 
their resting O2 saturations higher (98.2 ± 0.17%, p<0.001). All reported an ability index of I.  
 
6.3.2 PCr/ATP Ratio 
Adjustment for blood contamination as described above was applied to the cardiac spectra of 
seven patients with Eisenmenger syndrome and all six healthy volunteers. 
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The PCr / ATP ratio in patients with Eisenmenger syndrome was significantly lower than the 
healthy control group (1.55 ± 0.10 vs 2.17 ± 0.15, p = 0.004) (Figure 6.4). There was no 
correlation between PCr / ATP ratio and age (r = 0.12, p = 0.66). 
 
6.3.3 Cramer Rao Lower Bounds 
The CRLBs for the PCr peak were 5.3 ± 0.5% in the Eisenmenger syndrome group and 5.8 ± 
0.7% in the control group. The CRLBs for the γ-ATP peak were 6.5 ± 0.4% in the 
Eisenmenger group and 8.8 ± 0.5% in the controls. These values are all less than 10% 
indicating that the spectra were of good quality and reproducibility. 
 
6.3.4 Correlations with Echo Parameters 
There was no significant relationship between the PCr / ATP ratio and the radial systolic 
function of the RV, as measured by fractional area change, (r = 0.214, p = 0.5). There was, 
however, a weakly positive correlation between the longitudinal systolic function of the RV, 
assessed by TAPSE, and the PCr / ATP ratio, although this did not quite reach statistical 
significance(r = 0.48, p = 0.08). There was also a significant negative correlation between the 
right ventricular myocardial performance index, a measure of global RV function, and PCr / 
ATP ratio (r = -0.57, p = 0.04). 
 
6.4 Discussion 
This is the first study to investigate the myocardial energetics in patients with Eisenmenger 
syndrome and we have demonstrated that the myocardial energetic status of the 
interventricular septum, as expressed by the PCr/ATP ratio, is impaired when compared to 
healthy control subjects. This reduction in PCr/ATP ratio is present despite a maintained 
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biventricular systolic function as demonstrated by echocardiography (see section 4) which 
may suggest that the energetic abnormality precedes contractile dysfunction. Interestingly, 
Holloway et al demonstrated an 18% reduction in PCr/ATP ratio in lowlanders returning from 
a period at altitude, with a maintained systolic function, and hypothesised that a reduction in 
this ratio may be a universal response to hypoxia[322]. 
 
The active myocardial relaxation that occurs early in diastole is highly energy 
dependent[323]. Thus, processes that affect the energetic status of the myocardial would be 
expected to result in diastolic dysfunction. The impaired energetic status we have 
demonstrated in Eisenmenger syndrome, therefore, may contribute to the right ventricular 
diastolic dysfunction that we described in section 5.3.3. This is also suggested by the inverse 
relationship between the PCr/ATP ratio and MPI, an indicator of global ventricular 
performance. 
 
Other conditions associated with diastolic dysfunction, including hypertrophic 
cardiomyopathy (HCM), have also been shown to have abnormal energetic status. Abozguia 
et al demonstrated a PCr/ATP ratio of 1.28 in patients with HCM compared to a mean of 2.26 
in age matched healthy controls[316]. Whilst systolic function was normal in HCM patients, 
there was significant diastolic dysfunction that normalised after the administration of 
perhexiline along with an increase in PCr/ATP ratio. The hypertrophy in HCM is associated 
with mitochondrial dysfunction with subsequent impairment of contractile and relaxation 
reserves[324]. There is also microvascular dysfunction with inadequate myocardial blood 
flow in relation to the degree of hypertrophy[325;326]. Our results raise the question as to 
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whether patients with Eisenmenger syndrome may benefit from the administration opf 
perhexiline. 
 
It is well established that impaired energetics occurs in left ventricular failure of different 
aetiologies[314-316]. However, much less is known regarding the energetics of the right 
ventricle in RV failure. Daicho et al investigated the mitochondrial energy-producing ability 
of the RV myocardium in an animal model of pulmonary hypertension and subsequent RV 
failure[327]. They showed a reduction in the O2 consumption of the right ventricular 
myocardium that was inversely related to the MPI on echo, and associated with a decrease in 
the myocardial high energy phosphates. Seen in this context, the relative preservation of the 
RV contractile function in Eisenmenger syndrome raises the possibility that there is a further 
factor that protects the myocardium from failing. One possible factor may be altered substrate 
utilisation. 
 
Certainly, Jung et al demonstrated abnormal phosphate metabolism in HCM patients[328]. 
They hypothesise that one reason for this may be altered energy sources with a shift from 
fatty acid to glucose metabolism even in asymptomatic patients. The preferential use of 
glucose by the hypertrophied heart as its main energy substrate was also shown previously by 
Allard et al in an animal model of HCM[329]. This may be due to a down regulation of 
PPARα in hypertrophied myocardium which results in a switch in substrate utilisation from 
fats to glucose[323]. 
 
Sherpas have also been demonstrated to utilise glucose preferentially to fatty acids as a result 
of the lifelong hypoxia, and despite the absence of hypertrophy[196]. Moreover, Hochachka 
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et al reported a low PCr/ATP ratio in Sherpas[197]. They suggest that, in the absence of 
myocardial ischaemia or increased workload, this may be due to an accelerated glycolysis; the 
increased ADP concentration that results from the low PCR/ATP ratio leading to increased 
activity of the enzymes involved in aerobic glycolysis. Thus, it is possible that patients with 
Eisenmenger syndrome also utilise glucose in preference to fatty acids due to both the chronic 
hypoxaemia and the myocardial hypertrophy. The eventual failure of the RV that occurs in 
some patients with Eisenmenger syndrome may then be due to a progressive insulin resistance 
which eventually inhibits this preferential glucose utilisation, similar to the changes that occur 
in left ventricular failure[323].  
 
A further reason suggested by Jung et al to explain the low PCr/ATP ratio found in HCM 
patients is O2 limitation, resulting from low blood flow through narrowed intramural coronary 
arteries[328]. This is unlikely to be a factor in the heart in Eisenmenger syndrome as chronic 
hypoxia is known to induce coronary vasodilatation and remodelling of the coronary 
microcirculation resulting in an elevated basal coronary blood flow[330;331]. Thus it is 
reasonable to assume that the coronary circulation at rest is not a limitation in patients with 
Eisenmenger syndrome. This may explain in part why the PCr/ATP ratio that we have 
demonstrated in patients with Eisenmenger syndrome is higher than that shown in HCM by 
others in our group[316]. 
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Figure 6.1 An example of a typical 31 P cardiac spectra in a healthy 
control subject.  
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Figure 6.2  Transmitter and receiver 31P surface coil used in present study 
 
14 cm 31P surface coil 
 
Tuning rods 
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Figure 6.3 Survey images showing the position of the voxel of interest (VOI) and centre of the 31P coil 
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Figure 6.4 PCr / ATP ratios in healthy controls and patients with Eisenmenger syndrome.  
*** P<0.001 
 
 
*** 
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7. CONCLUSIONS 
 
7.1 Hypotheses 
1. Patients with Eisenmenger syndrome have severe exercise intolerance with an early 
shift to anaerobic metabolism (chapter 3). 
We have shown that patients with Eisenmenger syndrome have a severely limited exercise 
capacity. However, in contrast to our hypothesis, they do not appear to show an early shift to 
anaerobic metabolism despite the severe hypoxaemia, as judged by the point at which the 
anaerobic threshold occurs relative to maximal exercise. This ability to maintain aerobic 
metabolism occurs despite reductions at maximal exercise of determinants of O2 delivery 
including minute volume, respiration rate, heart rate and O2 pulse (stroke volume). This 
finding therefore suggested that in adults with Eisenmenger syndrome, the mitochondria in 
skeletal muscle have optimised their O2 utilisation. 
 
2. There are alterations in skeletal muscle mitochondrial metabolism to account for the 
exercise intolerance as assessed by the PCr recovery (chapter 4). 
Our results on lower leg skeletal muscle have demonstrated, in accord with our hypothesis, 
that patients with Eisenmenger syndrome have a maintained mitochondrial oxidative capacity, 
relative to control subjects, as measured by PCr recovery time following exercise to fatigue. 
We also showed that they have a similar reduction in intramuscular pH during exercise to 
healthy controls, again suggesting that they do not have an early reliance on anaerobic 
metabolism. 
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3. They have maintained cardiac systolic function but right ventricular diastolic 
dysfunction as measured by echocardiography (chapter 5).  
The present findings with echocardiography demonstrated that patients with Eisenmenger 
syndrome have preserved right and left ventricular systolic function. However, in agreement 
with our hypothesis, we provide evidence of right ventricular diastolic dysfunction as 
evidenced by impaired early diastolic relaxation.  
 
4. There is preservation of the septal energetics allowing maintenance of the contractile 
function (chapter 6).  
In agreement with our hypothesis, the results we obtained with 31P MRS demonstrated that 
despite the normal systolic function shown on echocardiography, there is impairment of septal 
energetics as revealed by a reduction in PCr/ATP ratio. From our results it is not clear if this 
reduction in PCr/ATP ratio represents sub-clinical ventricular dysfunction or is due to an 
increased reliance on glucose over fatty acids for metabolism.  
 
7.2 Adaptations to Hypoxaemia 
Overall, the results presented in this thesis indicate that adult patients with Eisenmenger 
syndrome have undergone beneficial adaptations to the severe hypoxaemia that they are 
exposed to from infancy.  As with lowlanders, such as mountaineers who acclimatise to 
hypobaric hypoxia, it is likely that time has allowed these adaptive processes to occur and 
allow them to survive despite PO2s that, if exposed to acutely, may be fatal[128;332]. The 
long term nature of their exposure may also explain why some of our results differ to previous 
studies carried out in children with cyanotic congenital heart disease[254;255].  
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The present findings demonstrated that patients with Eisenmenger syndrome, like other 
individuals exposed chronically to hypoxia, have increased haematocrit and increased 
ventilation at rest, both of which will help to increase the O2 delivery to the contracting 
muscle, providing these patients show adequate exercise hyperaemia; in future studies, 
measurements of blood flow during exercise are required to fully test this proposition. 
Notwithstanding, our MRS results indicated a preserved mitochondrial oxidative capacity in 
skeletal muscle as evidenced by the finding that from a similar level of PCr depletion caused 
by exhaustive exercise, they showed a preserved PCr recovery following exercise as 
compared to healthy controls. Further, although Eisenmenger patients showed a low cardiac 
PCr/ATP ratio relative to controls, it was preserved relative to other patient groups with HCM 
or left ventricular dysfunction. Thus, patients with Eisenmenger syndrome appear to have, 
through exposure to longstanding hypoxaemia, adapted metabolically to maintain their 
cellular energetics and function.  
 
As discussed in previous chapters, one mechanism by which patients with Eisenmenger 
syndrome may adapt to chronic hypoxaemia is by switching cardiac and skeletal muscle 
metabolism to a greater reliance on glucose for fuel rather than free fatty acids to maximise 
the generation of ATP per mole of O2 consumed. Hoppeler et al describe how long term or 
permanent exposure to profound hypoxia results in a reduced mitochondrial content of muscle 
fibres, a move towards increased metabolism of carbohydrates for oxidative metabolism and 
decreased intramyocellular lipid substrate stores[132]. Despite this reduction of mitochondria, 
there is improved high altitude performance which they argue is due to better coupling 
between ATP supply and demand pathways.  
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An important factor in the cell’s adaptive responses to hypoxia is through hypoxia-inducible 
factor 1(HIF-1) which acts as the “master regulator”, as discussed in chapter 1[168;333]. In 
normoxia the heterodimer HIF-1α is hydroxylated and targeted for proteasomal 
degradation[334]. However, in hypoxia it becomes stabilised and plays a central role in 
regulating the expression of numerous adaptive genes. These include those that enhance 
glucose metabolism, such as GLUT-1 and other glycolytic enzymes[179], and non-metabolic 
targets including erythropoietin and VEGF which lead to an increased O2 carrying capacity 
and the potential for increased O2 delivery. 
 
The switch from fatty acid to carbohydrate metabolism in cardiac muscle has been termed a 
switch to the fetal gene programme which maximises the production of ATP per mole of O2 
consumed[335]. Thus, Sharma et al, who followed the expression of the genes involved in 
glucose metabolism in rat hearts in response to hypobaric hypoxia, showed that the right 
ventricle showed an early switch to a fetal pattern of glucose predominance[335]. They 
suggested that since only the RV showed the switch, that the stimulus was the hypoxia 
induced increase in RV workload. 
 
Whilst the role of HIF-1α in chronic hypobaric hypoxia has been extensively investigated, 
only two studies to date have looked at the expression of HIF-1α and its target genes in 
cyanotic congenital heart disease (CHD). Lemus-Varela et al examined the mRNA transcripts 
for HIF-1α and its targets, VEGF and Epo, in newborn infants with cyanotic CHD and 
persistent pulmonary hypertension of the newborn, a condition also characterised by 
hypoxaemia[336]. They demonstrated increased expression of all of these substances in the 
hearts of cyanotic subjects compared to healthy non cyanotic newborns. Further, Qing et al 
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compared the expression and activity of HIF-1α, VEGF and eNOS in the ventricular 
myocardium of infants with cyanotic congenital heart disease and again found up-regulation 
of these substances compared to infants with non-cyanotic heart disease[337]. They also 
showed that the response was proportional to the degree of hypoxaemia.  Both of these studies 
were performed in infants, but it may be that this up regulation of HIF-1α continues with time 
and may explain, in part, our findings of preserved mitochondrial oxidative capacity. 
 
However, a complete switch to glucose metabolism is unlikely and would not be sustainable 
over time. A further mechanism to hypoxia may be the down regulation of mitochondrial 
uncoupling proteins. Uncoupling proteins (UCP) 2 and 3 are found in human heart and 
skeletal muscle cells and act to decrease the proton gradient across the inner mitochondrial 
membrane and thus decrease the ATP yield[338]. Up regulation of these is seen in acquired 
heart failure and contributes to the abnormal energetics status found and a shift towards less 
O2 efficient fatty acid metabolism [339].  
 
The expression of UCP2 and 3 is controlled by peroxisome proliferator-activated receptor 
(PPARα)[339]. The expression of PPARα and its target genes, including UCP2 and 3, has 
been demonstrated to be reduced in chronic hypoxia with Levett et al recently demonstrating 
a decreased expression of UCP3 in skeletal muscle in climbers exposed to sustained 
hypoxia[333]. The expression of PPARα  is again mediated by HIF1-α[340;341].  
 
Thus, exposure to chronic hypoxia appears to allow a switch away from fatty acid metabolism 
plus improved mitochondrial coupling with a subsequent preservation of cardiac and skeletal 
muscle contractile function despite low O2 availability.   
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A further potential mechanism in the adaptation to hypoxia may be through alterations in 
concentrations of nitric oxide and its metabolites.  Nitric oxide (NO) is an important 
signalling molecule that acts as an endogenous regulator of cell and tissue function[342]. 
Amongst its functions are effects on vascular tone as a vasodilator, thus affecting blood 
pressure and blood flow, and regulation of intermediary metabolism and mitochondrial energy 
production by competing with O2 for the same binding site on cytochrome oxidase[343]. NO 
is produced within the cell from L-arginine by NO synthases (NOS), an O2 dependent 
process, and is stabilised in the blood by oxidation to nitrate (NO3-) and nitrite (NO2-). NO can 
also be produced through the reduction of dietary NO3-and NO2-.  
 
Whereas NO3- and NO2- were previously considered to be inert by-products of NO metabolism 
it is now known that under hypoxic conditions, when O2 dependent NOS activity is 
compromised, NO2- is an important source of NO and maintains NO production through the 
reduction of NO2- by heme proteins[344]. Indeed, Maher et al demonstrated the hypoxic 
augmentation of the dilator action of NO2- on blood vessels in healthy individuals[345].  They 
showed that under hypoxic conditions, infusion of NO2- led to a significant increase in 
forearm blood flow compared to infusion during normoxia.  
 
In accord with this, Erzurum et al demonstrated that Tibetan highlanders have more than ten 
fold higher levels of active NO products within their circulation, including plasma NO2-, red 
cell NO3- and nitroso proteins, with a resultant increase in forearm blood flow and O2 delivery 
when compared to lowlanders[346]. Further to this, Levett et al in the Caudwell Xtreme group 
have shown an increase in plasma biomarkers and changes in microcirculatory blood flow in 
skeletal muscle of lowlanders acclimatising to altitude in the Caudwell Xtreme group[347].  
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Further  beneficial effects of increased levels of NO3- and NO2- have been shown by recent 
studies showing a decreased O2 cost of exercise following dietary supplementation with 
nitrates[348;349]. Thus, Larsen et al demonstrated a profound effect of dietary NO3- on 
mitochondrial function as well as whole body O2 consumption during exercise[349]. 
However, they also found a decreased expression in skeletal muscle of ATP/ADP translocase, 
a protein involved in proton conductance, and thus suggested that the mechanism for the 
improved function was through improved mitochondrial coupling between respiration and 
oxidative phosphorylation. Further to this they also found a trend towards down regulation of 
UCP3.  
 
Our results show a small increase in O2 delivery, as shown by total Hb in the NIRS study, at 
rest in patients with Eisenmenger syndrome compared to healthy controls. Whilst initially it 
was hypothesised in chapter 4 that this was likely due to an elevated O2 content of the blood 
secondary to an increase in haemoglobin, it is feasible that these patients also have elevated 
levels of NO and its metabolites with subsequent increase blood flow within the 
microcirculation.  Furthermore, elevated levels of circulating NO metabolites in these patients 
may have a further beneficial effect through improved mitochondrial coupling and more 
efficient metabolism.  
 
Whilst it is clear that patients with Eisenmenger syndrome have adapted in many beneficial 
ways to a life time of severe hypoxaemia, it cannot be overlooked that they remain severely 
limited in exercise when objectively assessed.   
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The cause of their limitation is probably multifactorial, with an inability to increase their 
cardiac output sufficiently, as shown by a reduced peak O2 pulse (stroke volume), and 
decreased O2 delivery to exercising muscle likely to be important contributing factors. 
However, in the experiments described in chapter 3, all of the patients stated shortness of 
breath as the primary reason for stopping exercise during cardiopulmonary exercise testing. 
This was despite them achieving a lower respiratory rate and tidal volume compared to 
healthy controls at peak exercise.  Some of the subjects with Eisenmenger syndrome also 
failed to reach maximal exercise, not reaching their anaerobic threshold or an RER>1.0. This 
suggests a further mechanism limiting their exercise capacity.   
 
Whereas the traditional theory of exercise limitation, suggested by Hill et al in 1924, is that 
mVO2 is limited by the cardiovascular system, with the heart limiting the amount of blood 
pumped to the exercising muscle resulting in anaerobic metabolism and lactic acidosis[350], 
an alternative centrally driven model has more recently been suggested and may partly 
explain our observations. 
 
The central governance model states that the extent of skeletal muscle recruitment is 
determined by the magnitude of central neural drive, in turn determined by feedback from 
peripheral factors[351]. Thus, exercise can be affected by physiological and psychological 
factors before exercise, such as the physiological state of the subject, expectations of duration 
and level of self belief, and during exercise there is continuous feedback to the brain from all 
organs including state of fuel reserves and hydration state. This has been described as a model 
of anticipatory regulation of exercise performance. 
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Whilst patients with Eisenmenger syndrome undoubtedly may have physiological reasons for 
their severe exercise intolerance, this centrally driven limitation would help explain why they 
stop before reaching their maximal level of exercise and, as shown by our skeletal muscle 
MRS data, do not appear to rely on anaerobic metabolism. Patients with Eisenmenger 
syndrome have lived with severe hypoxaemia and pulmonary hypertension all of their life 
and, whilst the majority report a good Ability index, have probably modified their activity to 
cope within their known limits, thus they become “contented invalids”. Therefore, exercising 
on a treadmill was likely to be a significant challenge for them and it is plausible that 
psychological factors, such as a pre-conceived perception of not being able to exercise for 
long or a low level of self-belief, may have led to a centrally driven premature cessation of 
exercise.  
 
A relationship between centrally-mediated exercise limitation and hypoxaemia has been 
previously reported in healthy subjects. Thus, Kayser et al demonstrated a decrease in EMG 
activity and lactate concentration during maximal exercise by acclimatised subjects at an 
altitude of >5000m compared to values obtained at sea level[352]. Furthermore, Annan et al 
showed that in acute severe hypoxia, exercise was terminated at lower levels of peripheral 
fatigue than in normoxia or moderate hypoxia[270;353]. These authors concluded that in 
acute severe hypoxia, the decision to terminate exercise is due to decreased central motor 
output and this precedes the development of significant peripheral muscle fatigue. This has 
led them to suggest that the lactate paradox, as discussed in chapter 4, may result from altered 
behavioural responses with in the brain rather than due to altered skeletal muscle 
metabolism[354]. 
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Further to the adaptations shown by skeletal muscle, our studies have looked at adaptations by 
cardiac muscle. Our results show that patients with Eisenmenger syndrome have overall 
preserved systolic ventricular function. Whilst they have a reduced PCr/ATP ratio at rest it is 
not clear from our results if this is due to an increased reliance on carbohydrates for 
metabolism or represents sub-clinical ventricular dysfunction. It is known however that the 
onset of RV failure in these patients is associated with a poor outcome. Therefore, 
understanding the underlying causes of the deterioration in RV function, and being able to 
correctly predict its onset, may lead to the development of therapeutic options to treat it.  
 
A recent study by Drake et al used a mouse model of pulmonary artery banding, to induce RV 
hypertrophy, with and without hypoxia to compare the gene expression pattern that 
distinguishes between adaptive RVH and RVF[355]. They showed that the genes that 
discriminate between these two phenotypes include those for growth and angiogenesis factors 
and enzymes involved in energy metabolism. Whilst confirmation of these changes in human 
studies is awaited, these may allow the future prediction of the development of RVF in 
Eisenmenger syndrome.  
 
Rondelet et al used a pig model to look at the effects of prolonged systemic to pulmonary 
shunting to investigate the effects on right ventricular function[356]. They demonstrated right 
ventriculoarterial uncoupling, as expressed by the ratio of end-systolic to pulmonary arterial 
elastance, with accumulation of the extracellular matrix, activation of apoptotic pathways and 
an increase in the expression of pro-inflammatory cytokines in the right ventricular 
myocardium. This maladaptive process led to decompensated RV failure. Whilst the authors 
state that this may have been due to the inability of the porcine heart to sustain a prolonged 
 147
increase in cardiac output and afterload, it is feasible that subjects with Eisenmenger 
syndrome are protected from these maladaptive changes until late on in the disease process. 
Further studies looking at the ventriculoarterial coupling in these patients, such as by the 
method described by Sanz et al using cardiac MRI and right heart catheterisation[295], may 
help predict the onset of RV decline. 
 
In conclusion, the studies described in this thesis indicate that the surprisingly good survival 
of patients with Eisenmenger syndrome, despite adverse cardiopulmonary haemodynamics 
and a lifetime of severe hypoxaemia, is due, in part, to beneficial physiological adaptations of 
both skeletal and cardiac muscle.  However, whilst they appear to be well adapted to life at 
rest, sustained exercise is not feasible. 
 
Other studies have shown similar adaptations occur in healthy adults during acclimitisation to 
high altitude. The normal cardiac anatomy that exists in these individuals eliminates the 
confounding effects of disease and therapeutic interventions that may complicate 
interpretation of findings made in Eisenmenger patients. However, the results obtained in 
acclimatised lowlanders may themselves be confounded by the effects of the hypobaric 
atmosphere at altitude and also the known effects of endurance training on muscle 
metabolism[65]. We have shown, by the results presented in this thesis that these adaptations 
can also occur in the presence of severe cardiopulmonary disease. This gives support to 
lending these findings to critically ill patients. 
 
 
. 
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7.3 Limitations of Study 
All of the studies described in this thesis were non-invasive with the exception of the venous 
blood samples taken in chapter 3. Our planned methodology initially included taking a 
skeletal muscle biopsy from these patients. However, we subsequently decided this carried an 
unacceptable risk to these patients due to the risk of bleeding[15;357]. A further proposed 
experiment was the calculation of the respiratory quotient (RQ) within the exercising muscle. 
The RQ is the ratio of CO2 produced and O2 consumed and gives further information 
regarding substrate utilisation. A RQ of 1.0 being indicative of glucose being the predominant 
fuel whilst a RQ of 0.7 suggesting fatty acids. However, this would have required obtaining a 
blood sample from an artery which again was felt to carry an unacceptable risk to the patient. 
 
Thus, the interpretations of our findings have been drawn on largely non-invasive 
measurements. Some of our conclusions are therefore based on assumptions with respect to 
exercise physiology in these complex cardiac patients.  
 
The numbers of patients with Eisenmenger syndrome who agreed to participate in this study 
was small.  The study was initially powered for 13 subjects to enable to us to detect a 20% 
difference in PCr/ATP ratio, but just 7 for a 20% difference in PCr recovery half time. The 
small numbers recruited reflects a relatively small cohort of patients with Eisenmenger 
syndrome in the modern era of ACHD from which to draw, which is made smaller when 
patients with Down syndrome are excluded.  
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7.4 Future Work 
Whilst our work demonstrated that beneficial physiological adaptations have indeed occurred 
in adult patients with Eisenmenger syndrome, future studies would be required to determine 
the exact mechanism underlying these adaptations. However, due to the risk to the patient of 
invasive procedures as outlined above, future studies would similarly need to avoid these and 
would therefore need to focus on non invasive experiments. The specific areas that warrant 
further investigations are outlined below.  
 
7.4.1 HIF-1α Activity 
The expression of HIF-1α and its target genes such as GLUT-1 and other glycolytic genes as 
well as non-metabolic genes such as EPO and VEGF, would help to give further information 
regarding their roles in the long term adaptation to the chronic hypoxaemia. It may also give 
further information as to the substrate utilisation in these subjects. This would be performed 
by isolating mRNA from white blood cells in peripheral  blood as described by Lemus-Varela 
et al[336]. 
 
7.4.2 Nitric Oxide and its Metabolites 
To further assess the NO availability in these patients we would assess the circulating 
biomarkers of NO availability in venous blood including nitrite, nitrate and S-nitrosothiols at 
rest and following exercise. 
 
7.4.3 Effects of Exercise on Cardiac Function 
All of our cardiac data was obtained at rest. Exercise echo would allow investigation of 
systolic and diastolic function as well as pulmonary artery pressures during exercise. Exercise 
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echo has previously been demonstrated to reveal widespread systolic and diastolic 
abnormalities in both hypertensive patients and patients with heart failure with preserved 
ejection fraction[306;358;359]. Therefore, this may give further insight into the cause of the 
exercise limitation.  
 
7.4.4 Ventriculo-arterial Coupling 
To further assess the proposal made above that maintenance of ventriculo-arterial coupling in 
part explains the preservation of ventricular systolic function, and it is the uncoupling that 
leads to RV failure, this could be further investigated to see if it is possible to predict the 
onset of RV failure. Whilst assessment of this has previously required invasive cardiac 
catheterisation, Sanz et al describe a non-invasive technique using cardiac MRI to 
approximate the degree of right ventriculo-arterial coupling[295].  
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ABSTRACTS AND PRESENTATIONS ARISING FROM THIS WORK 
 
· Fatigue and Exercise Intolerance in Eisenmenger syndrome 
  Oral presentation in “Young Investigator” competition at BCCA 2009 
 
· Resting Skeletal Muscle Oxygen Consumption and Maximal Oxidative Capacity in 
Eisenmenger Syndrome 
  Poster presentation at BCCA 2009 (winner of “best poster”) 
 
· Right Ventricular Function and Cardiac Energetic Status in Eisenmenger Syndrome 
 Poster presentation at BCCA 2009 
 
· Exercise Intolerance and Skeletal Muscle Adaptations in Eisenmenger Syndrome 
 Oral presentation in “State of the Art” session at ESC 2009 
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